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ABSTRACT
STUDIES ON TYPE I AND TYPE II DNA TOPOISOMERASES FROM 
MAMMALIAN MITOCHONDRIA
Jia-Hwei Lin
Old Dominion University 
and
Eastern Virginia Medical School 
1993
Director: Frank J. Castora, Ph.D.
Mammalian mitochondria contain a unique DNA topoisomerase 
I with characteristics of both nuclear and bacterial type I 
DNA topoisomerases. This enzyme, purified from bovine liver, 
requires cations as cofactors and possesses optimal activity 
at pH 7.0, 37°C and either 150 mM K+ or Na+ ions. Similar to 
nuclear enzymes and different from the bacterial enzyme, 
divalent ions such as Ca2+ or Mg2+will stimulate but are not 
essential for the enzymatic activity.
Like the nuclear DNA topoisomerase I, the mitochondrial 
enzyme is capable of relaxing both negatively and positively 
supercoiled DNA. The relaxation of negatively supercoiled DNA 
is directly inhibited by camptothecin and indirectly by m- 
AMSA, a DNA intercalator. The relaxation of positively 
supercoiled DNA is also inhibited by camptothecin, however, 
with 10 to 20 fold less efficiency.
Like all DNA topoisomerases, the mitochondrial enzyme 
forms a transient enzyme-substrate complex through a phospho- 
tyrosyl covalent linkage. This linkage was found to be at the 
5' terminus of the DNA break, a manner similar to the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
bacterial DNA topoisomerase I . Mitochondrial DNA topoisomerase 
I slightly cross-reacts with antibody raised against nuclear 
DNA topoisomerase I indicating the partial similarity of the 
structure of the mitochondrial and nuclear enzymes.
Recognition of the DNA substrate was found to be non- 
random judging from the distinct cleavage patterns of DNA 
cleavage assay results. Analysis of the sequences around 79 
sites cleaved by the nuclear and mitochondrial enzyme 
indicated no consensus sequences, though a preference of T 
(43%, P = 0.01) at the -1 position was found.
There were three sites showing a strong preference for 
cleavage by this mitochondrial DNA topoisomerase I. All three 
had a G at the -1 position. Furthermore, these sequences can 
form a cruciform structure with distinct features no other 
cleavage sequences analyzed so far possess.
Mitochondrial DNA topoisomerase I can bind to both single­
stranded and double-stranded DNA with a preference for the 
latter. This preference differs from both the nuclear enzyme, 
which has no preference for either forms of DNAs, and the 
bacterial enzyme, which prefers single stranded DNA.
A DNA topoisomerase II has also been partially purified 
from calf thymus mitochondria. This enzyme unknots DNA in the 
presence of ATP. Two type II DNA topoisomerase-targeting 
antitumor drugs, m-AMSA and VM-26, are able to inhibit the 
unknotting activity at concentrations above 0.5 /uM.
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Chapter I. INTRODUCTION
A. Background and significance
The topological structures of DNA pose an interesting 
problem in regulating cellular functions. A standard B form 
DNA duplex has a pitch of 10.4 base pairs per helical turn. 
A closed circular DNA with 10.4 base pairs per helical turn 
has no torsional strain and is called relaxed. During 
replication and transcription of genomic DNAs, the double 
helical structure of DNA is subject to conformational and 
topological strain resulting in underwound regions falling 
behind and overwound regions ahead of the replication fork. 
DNA topoisomerases are enzymes that interconvert topological 
structures of DNA to facilitate replication, transcription and 
other genetic processes by modifying the topological state of 
DNA using functions similar to those of scissors and glue. 
Topological structures of DNA can be described in part by the 
linking number. The linking number, defined as the number of 
times the two strands cross one another, of a relaxed DNA is 
termed a°. DNA species with a linking number lower than a0 are 
said to be negatively supercoiled. A positively supercoiled 
DNA has a linking number higher than a°. Examples of DNA 
topoisomerase catalyzed reactions are the interconversion of
1
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supercoiled and relaxed, knotted and unknotted, and catenated 
and decatenated DNAs.
DNA topoisomerases can be categorized into two types based 
on the mechanism of enzyme action on the substrate DNA. Type 
I DNA topoisomerases break one strand of the duplex DNA, 
passing the unbroken strand through the single-stranded break, 
and resealing the broken strand resulting in a change in the 
linking number by one unit. On the other hand, type II DNA 
topoisomerases alter the linking number in steps of two by 
breaking both strands, unwinding the intact double strands and 
resealing the break using the energy generated by hydrolysis 
of ATP. These enzymes have been found in a variety of 
organisms, including prokaryotes, such as E. coli (1) , M. 
luteus (2), viruses, such as bacteriophage T4 (3) , and in the 
nuclei and organelles of eukaryotes.
In prokaryotes, E. coli DNA topoisomerase I (& protein) 
(1) and DNA topoisomerase II (DNA gyrase) (4) have been well 
studied. The gene coding for the E. coli. DNA topoisomerase 
I has been isolated and designated as topK (5). Top A encodes 
a peptide with a molecular weight of 110,000 daltons. This 
enzyme acts as a monomer and requires magnesium for its 
catalytic activity. A tyrosine residue in the active site of 
the enzyme is responsible for a transient covalent linkage in 
the enzyme-substrate intermediate (6). This linkage is formed 
between the hydroxyl group of tyrosine and the phosphate group
2
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at the 5' end of the DNA break. In vitro, this enzyme is only 
capable of relaxing negatively supercoiled DNA, and its 
relaxation activity is inhibited by the addition of single­
stranded DNA. The fact that this enzyme reacts with single­
stranded DNA was demonstrated by its ability to knot and 
unknot the single-stranded circles of phage fd DNA (7) . Thus, 
the preference of this enzyme to relax negatively supercoiled 
DNA can be due to the presence of transient single-stranded 
DNA regions in negative but not positive supercoiled DNA.
DNA gyrase is composed of a pair of two polypeptides, A2B2, 
and catalyzes the negative supercoiling of DNA at the expense 
of ATP hydrolysis (4). It preferentially relaxes positively 
supercoiled DNA in the presence of ATP, while it relaxes 
negatively supercoiled DNA without ATP. It is also able to 
catenate and decatenate duplex DNA. The two genes gyrA and 
gyrB each of which encodes one of the two subunits of gyrase 
have been cloned. The A protein, which is sensitive to 
nalidixic acid (8) and oxolinic acid (9), has a molecular 
weight of 100,000 daltons; the B protein, which is inhibited 
by coumermycin A1 and novobiocin, has a molecular weight of 
about 90,000 daltons. Oxolinic acid has been proven to 
inhibit both the relaxation and the supercoiling activity of 
DNA gyrase. This inhibitory effect indicates that the A 
protein is involved in the cleavage and resealing reaction 
(9). Also, hydrolysis of ATP requires duplex DNA and is 
inhibited by coumermycin and novobiocin (10). Therefore, the
3
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B protein is responsible for ATP hydrolysis. Neither subunit 
has activity on its own (8) . Like the prokaryotic DNA 
topoisomerase I# DNA gyrase also forms a phosphotyrosyl 
linkage at the 5' end of the DNA breaks. The A protein is 
involved in the linkage and makes a four base pair staggered 
cleavage (11).
In higher organisms, DNA topoisomerases I and/or DNA 
topoisomerase II from yeast (12), wheat germ (13), Xenopus 
laevis oocytes (14), and Drosophila (15, 16) have been
isolated. DNA topoisomerases from several mammalian cell 
lines have also been studied, including those from calf thymus 
(17), rat liver (18, 19), and cultured human HeLa cells (20). 
The eukaryotic DNA topoisomerase I differs from its 
prokaryotic counterpart in its ability to relax both 
positively and negatively supercoiled DNAs. Divalent cations 
are not required for the catalytic activities of eukaryotic 
enzymes, but they have been shown to stimulate them (18) . 
Several eukaryotic type I DNA topoisomerase genes have been 
identified, and no sequence homology with the prokaryotic 
enzyme was found. In addition, a phosphotyrosyl bond is found 
at the 3' terminus rather than the 5' terminus of the DNA 
break (21).
Type II DNA topoisomerases in eukaryotic cells and phage 
T4 lack the ability to introduce supercoiling, but they are 
able to relax both positive and negative supercoils in the
4
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presence of ATP (22). The eukaryotic DNA topoisomerase II 
functions as a homodimer, which has homology with both 
subunits of DNA gyrase (23). This enzyme also attaches to the 
5' phosphoryl group of the DNA break through a tyrosine 
residue.
The transient covalent linkage between DNA and DNA 
topoisomerases has been demonstrated by using a phosphoryl 
transfer assay (24). The substrate DNA is uniformly 
radiolabeled by nick translation and incubated with the 
enzyme. Upon addition of denaturants, such as sodium dodecyl 
sulfate (SDS), the transient enzyme substrate intermediate is 
trapped and is termed the "cleavable complex". If a covalent 
linkage occurs, the radioactive phosphate group will remain 
attached to the enzyme after degradation of the DNA with DNase 
I. Thus, the enzyme will be radiolabeled and it can be 
visualized by autoradiography after separation on a SDS 
polyacrylamide gel (SDS-PAGE) by gel electrophoresis. A 
conclusion can be drawn that among type I DNA topoisomerases 
the covalent linkage to the DNA break is at the 3f terminus 
for eukaryotic enzymes and at the 5' terminus for prokaryotic 
enzymes. However, all type II DNA topoisomerases have been 
identified as binding to the 5' terminus of the DNA break. In 
all cases, the amino acid involved in the covalent linkage was 
identified as tyrosine.
Mammalian mitochondria contain multiple copies of a single
5
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circular DNA of approximately 16,500 base pairs. Other than 
the displacement (D-loop) region, most of the mitochondrial 
genome is double-stranded and supercoiled (25). The D-loop 
region is the location of the replication origin of the heavy 
strand and is covered by a variety of the single-stranded DNA 
binding proteins (26-28). Mitochondria and the mitochondrial 
genome are capable of self replication and the replication of 
mitochondrial DNAs starts with the heavy strand. The light 
strand does not replicate until almost two thirds of the heavy 
strand is replicated (29). This replication process of 
circular DNAs generates extra topological tension which must 
be relieved to allow the movement of the replication fork to 
continue. A variety of DNA binding proteins (26-28, 30)
facilitate the replication of the DNA, stabilize the structure 
of the DNA, and maintain the proper topology of the DNA during 
replication. Therefore, the existence and role of DNA 
topoisomerases in mitochondria are important issues. DNA 
topoisomerases in mitochondria would be likely candidates to 
participate in the replication processes mentioned above. 
Furthermore, the separation of the circular DNA after 
replication and the maintenance of the proper degree of 
supercoiling at various stages of the cell cycle are other 
obvious functions of DNA topoisomerase in mitochondria.
In 1979, Fairfield et al. (31) reported the existence of 
DNA topoisomerase I activity in rat liver mitochondria. 
Intramitochondrial DNA topoisomerase I activity has also
6
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been found in mouse L cells (32) and Xenopus laevis oocytes 
(33). DNA topoisomerase I in calf thymus mitochondria has 
been identified and isolated by Lazarus et al. in 1987 (34). 
The existence of DNA topoisomerase I in human mitochondria has 
been further substantiated by Kosovsky and Soslau (35) using 
human platelets, which do not contain nuclei.
A type II DNA topoisomerase activity has also been 
observed in the mitochondria of rat liver cells (Castora et 
al., 1982) (36) and human leukemia (HALL) cells (Castora et
al., 1985) (37). From the kinetoplasts of the Trypanosomatid 
Crithidia fasciculata, Melendy and Ray (38) have purified a 
mitochondrial type II DNA topoisomerase. This purified enzyme 
is capable of ATP-dependent catenation and decatenation of 
kinetoplast DNA networks as well as catalyzing the relaxation 
of supercoiled DNA. However, due to the limitations of 
obtainable tissues, no mammalian mitochondrial DNA 
topoisomerase II has yet been purified. Moreover, no other 
detailed studies of mitochondrial DNA topoisomerases have been 
performed.
In addition to the DNA topoisomerases mentioned above, 
various DNA topoisomerases with similar or distinct catalytic 
properties have also been found. In plants, a DNA 
topoisomerase I has been partially purified from an extract of 
spinach chloroplasts (39). This topoisomerase resembles 
prokaryotic DNA topoisomerase I in its requirement for
7
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magnesium ions and its relaxation of only negatively 
supercoiled DNA. Another type I DNA topoisomerase, DNA 
topoisomerase III, has been identified from E. coli (40) and 
has enzymatic properties similar to DNA topoisomerase I. From 
archebacterium Sulfolobus acidocaldarius (41), a reverse 
gyrase was isolated. This enzyme utilizes ATP hydrolysis to 
introduce positive supercoils into DNA at a reaction 
temperature of 75°C.
Under certain conditions DNA topoisomerases can function 
as strand-transferases by sealing the enzyme-attached strand 
to a strand of another DNA substrate (42). There are also 
enzymes, whose normal function is DNA strand transfer, which 
can catalyze DNA topoisomerization. Examples of this class of 
enzymes includes the gene A protein of phage 0X174 (43), the 
gene 2 protein of phage fd (44), the phage lambda int gene 
product (45), and the resolvases Tn3 and yS of transposons 
(46, 47). The existence of multiple DNA topoisomerases and 
enzymes with similar activities in one cell is evidence that 
the degree of supercoiling of DNA is regulated constantly 
during the life cycle of a cell.
The nuclear DNA topoisomerases have been found to be the 
target of a number of anti-tumor drugs either in vitro or in 
vivo. Camptothecin, a plant alkaloid isolated from 
Camptotheca acuminata, is the only antitumor drug which 
selectively inhibits the activity of eukaryotic DNA
8
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topoisomerase I (48). Treatment of S-phase cells with 
camptothecin causes fragmentation of the chromosomal DNA (49), 
induction of sister chromatid exchanges (50), retardation in 
both RNA synthesis and DNA replication (51) and cell death. 
However, camptothecin has no effect on prokaryotic DNA 
topoisomerase I.
Differing from type I enzymes, DNA topoisomerase II is 
targeted by a variety of antitumor drugs, which can be divided 
into two categories, DNA intercalators and nonintercalators. 
Among the DNA intercalators, acridines (52), e.g. m-AMSA, 
anthracyclines (53), e.g. adriamycin, actinomycin D (54) and 
ellipticines (55) have been extensively studied. 
Epipodophyllotoxins (56), e.g. VM26, and isoflavonoids, e.g. 
genestein, are nonintercalators. Similarly to the effect of 
camptothecin, these DNA topoisomerase II poisons provoke 
sister chromatid exchanges and cause chromosomal aberrations. 
These type II enzyme inhibitors also cause blockage of cell 
mitosis in late S and G2 phases (57).
As mentioned earlier, the activity of bacterial DNA gyrase 
is inhibited by antibiotics. They are the coumarins, 
including novobiocin and coumermycin Al, and quinolones, 
including nalidixic acid and oxolinic acid. Of the type II 
enzyme poisons, all except m-AMSA exhibit inhibitory effects 
on bacterial DNA topoisomerase II. However, the DNA 
topoisomerase II from the Crithidia fasciculata kinetoplasts
9
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was inhibited in vitro by m-AMSA, VP16-213 and VM-26 (58) and 
Shapiro et al. (59) demonstrated in vivo drug-promoted 
cleavage of kinetoplast DNA minicircles.
The mechanism of antitumor drugs in inhibiting DNA 
topoisomerases activity has been investigated. DNA 
intercalators inhibit the relaxation activity of the enzyme by 
intercalating into the DNA preventing the binding of the 
enzyme to the DNA. Non-intercalators inhibit the resealing 
action of the enzyme resulting in the breakage of the DNA. 
However, not all the DNA intercalators are able to inhibit the 
enzyme activity which suggests that these drugs directly 
interfere with the function of DNA topoisomerases. This 
theory is based on the fact that ethidium bromide, even though 
it is a strong intercalator, shows no antitumor activity. 
Besides, o-AMSA, which is an analogue of m-AMSA and 
intercalates DNA as well as m-AMSA, has much weaker antitumor 
activity (60). This leads to a hypothesis made by Nelson et 
al. (60) stating that the formation of a drug-enzyme-DNA 
ternary complex is a key step in the inhibitory effect of 
drug. Furthermore, some DNA topoisomerase II inhibitors, such 
as the coumarins, may act by competing with ATP for binding to 
the enzyme.
By interfering with the breakage-resealing reaction of DNA 
topoisomerases, these antitumor drugs stabilize the "cleavable 
complex" which results in the breakage of the DNA. Use of
10
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these drugs has helped in the detailed study of the mechanism 
of the enzymes.
A DNA cleavage assay based upon the formation of cleavable 
complexes showed that nuclear DNA topoisomerases cleaved DNA 
in a nonrandom fashion (61, 62). The presence of antitumor 
drugs strongly stimulates the cleavage reaction and some 
inhibitors even generate new DNA cleavage sites. Though no 
consensus sequences were identified, a preference for T at 
position -1 to the cleavage site was observed and a loosely 
defined 5 base pair sequence (-4 to +1) was revealed for 
eukaryotic DNA topoisomerase I. For prokaryotic DNA 
topoisomerase I, a preference for C at the -4 position was 
derived, even though poly(dT), poly(dC) and short 
homo-oligomers of all four nucleotides can be cleaved by the 
enzyme (63).
A specific cleavage sequence for human DNA topoisomerase 
I has been identified by Westergaard and coworkers (64), and 
DNA topoisomerase I preferentially relaxes supercoiled DNA 
containing a sequence of 5/-AAAAAAGACTT*AGAAAAATTTT-3/ (* 
indicates the cleavage site) (65). Shuman identified a 
pentameric sequence motif (C/T)CCTT as a specific DNA cleavage 
site by Vaccinia virus DNA topoisomerase I (66) . The lack of 
a definite consensus sequence for DNA cleavage leads to the 
suggestion that the conformation of the DNA may play a role in 
recognition by DNA topoisomerases. Using single stranded-DNA,
11
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cleavage has been shown to occur in the regions capable of 
base pairing (67). Shen et al. in 1989 concluded that a 
similar local twist angle occurs in over one hundred DNA 
topoisomerase I cleavage sites analyzed (68). Up to now, no 
single theory is able to explain how DNA topoisomerases 
recognize their substrate DNA.
B. Statement of problem
Much has become known about the DNA topoisomerases in 
nuclei and in bacteria, but few detailed studies of mammalian 
mitochondrial DNA topoisomerases have yet been performed. The 
purpose of this project is to study the function and role of 
mammalian mitochondrial DNA topoisomerases. Since
mitochondria are the power factories of the cell, the quantity 
of mitochondria in each cell is controlled by the energy 
requirements of the cell. The effects of the mitochondrial 
DNA topoisomerases on the replication and transcription of the 
mitochondrial genome indirectly affect the metabolism of the 
cell. Studies on these mitochondrial enzymes will help us 
understand the regulation of the mitochondrial genome as well 
as the relationship between the mitochondria and the whole 
cell.
Two types of DNA topoisomerases, Type I and Type II, will 
be isolated and purified for enzyme characterization. In 
enzyme characterization, the optimal reaction condition for
12
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the enzymes will be investigated. The physical properties, 
such as the molecular weight, the K,,, value, and the V,^ of the 
enzymes will be determined.
The interaction of the enzymes with the substrate DNA will 
be studied. Whether the mitochondrial enzyme recognizes and 
cleaves DNA in a random or nonrandom fashion will be 
investigated. Furthermore, the existence of a covalent bond 
in the cleavable complex and the determination of the covalent 
binding site as either at the 3' terminus or 5' terminus of 
the DNA break will be pursued. Any preferential binding in 
substrate DNA structures and sequences by the mitochondrial 
enzyme also falls within the scope of this study.
Although reports have demonstrated the inhibition of the 
catalytic activity of nuclear topoisomerases and kinetoplast 
DNA topoisomerase II by a variety of antitumor drugs, there 
have been no similar reports for mammalian mitochondrial 
topoisomerases. One of the goals for this study is to test 
the sensitivity of these mitochondrial enzymes to various 
antitumor drugs.
These studies will help researchers to understand the 
function of mitochondrial DNA topoisomerases and hopefully to 
distinguish the mitochondrial enzyme from its nuclear 
counterpart. This may have an impact on our understanding of 
the role these enzymes play in mitochondrial biogenesis. The
13
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characterization of their behavior towards the antitumor drugs 
may influence our development of successful therapies for 
cancer and/or other pathological conditions.
14
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Chapter II. MATERIALS AND METHODS
A. Materials
Plasmid pUC19 DNA was isolated from HB101 cells harboring 
the plasmid by lysing the cells with alkaline-SDS followed by 
cesium chloride centrifugation in the presence of ethidium 
bromide. The P4 phage and its host cells were gifts from Dr. 
Leroy Liu. The P4 knotted DNA is isolated from the protocol 
listed in the appendix I. Mitochondrial DNA was recovered 
from the purified bovine liver mitoplasts. Taq DNA polymerase 
was purchased from Perkin-Elmer/Cetus. EcoRI, Hindlll and 
Nick translation system (cat # 8160SB) were from Gibco BRL. 
All other restriction enzymes and fmol DNA sequencing system 
were purchased from Promega. Bacterial DNA topoisomerase I 
was a kind gift from Dr. Y. Tse-Dinh, New York Medical 
college, N.Y. Camptothecin,, m-AMSA, VM-26, Cellulose 
phosphate, hydroxylapatite, phenyl agarose, double stranded 
DNA cellulose were from Sigma. Phosphoserine, phospho- 
threonine, and phosphotyrosine were also from Sigma. All 
radioactive nucleotides, including [gamma-32P] ATP (3000 
Ci/mmol) , [a-32P]dCTP (400 Ci/mmol) and [3H]dTTP (10 Ci/mmol) 
were purchased from New England Nuclear. DNA grade agarose, 
acrylamide and bis-acrylamide were from Fisher. All other
15
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chemicals were of analytical grade or higher.
B. Equipment
E-C 103 power supply by E-C Apparatus Corporation was used 
for agarose gel electrophoresis. Both MBP 3000D
Electrophoresis power supply and DNA sequencing system by IBI 
were used for DNA sequencing. Stratagene pressure control 
station, Posiblot apparatus, and Stratagene UV stratalinker 
1800 were used for DNA transfer. UV transilluminator was from 
UVP, Inc. The camera system was an MP-4 Land camera from 
Polaroid. LKB Ultrascan XL enhanced laser densitometer was 
used for scanning gels. DNA samples were concentrated in a 
Savant speed-vac. concentrator connected to a Savant 
refrigerated condensation trap. A Biorad model 83 slab dryer 
was used for gel drying. DNA primers were synthesized in a 
Cyclone DNA synthesizer by Biosearch, Inc.
C. Methods
Protein determination;
Protein was measured by biuret analysis (69) at the early 
stages of purification and by the method of Bradford (70) 
after the column chromatography. Bovine serum albumin was 
used as standard protein in either procedure.
16
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Marker enzvme assays:
Glucose-6-phosphate dehydrogenase, sulfite oxidase, 
succinic dehydrogenase, amine oxidase and DNA polymerases 
alpha and gamma were assayed essentially as described in (71). 
The amount of polymerase beta and gamma activity that 
contributed to the alpha polymerase assay was determined by 
performing an alpha polymerase assay in the presence of 
aphidicolin. This corrected activity, pol alpha', was 
calculated from the following equation:
pol alpha' = pol alpha (total) - pol alpha (plus 
aphidicolin)
and was used to calculate the ratio of gamma to alpha 
polymerase in the final preparation.
Isolation of DNA topoisomerases:
Nuclear DNA topoisomerase I was purified from the calf 
thymus according to the published procedure (72).
Mitochondrial DNA topoisomerase I was either purified from 
the calf thymus by the previously published procedure (34) or 
from the bovine liver by the modified procedure listed in 
appendix II.
Mitochondrial DNA topoisomerase II was purified as stated 
below. The mitochondria, mitoplasts and the inner membranes
17
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were isolated essentially as described in the previously 
published procedure (34). A protease inhibitor cocktail (1 mM 
of PMSF, 0.7 mg/L of pepstatin A, 0.5 mg/L of leupeptin, 1 mM 
of sodium sulfite, 0.5 mM of EDTA, 1 mM of 2-Mercaptoethanol) 
was included in all steps after lysis of the purified 
mitoplasts. All potassium phosphate (KPi) buffers were pH 
7.3. The inner membranes were solubilized with Triton X 100 
in 150 mM KPi / 1.0 M NaCl / 20% glycerol and the
mitochondrial DNA was removed by polyethylene glycol (PEG) 
precipitation. After centrifugation, the PEG-supernatant was 
diluted with 20% glycerol to 0.33 M NaCl and loaded on a 
phosphocellulose column equilibrated with 50 mM KPi / 0.33 M 
NaCl / 20% glycerol. After washing with three bed volumes of 
starting buffer, the enzyme was eluted with 50 mM KPi / 0.8 M 
NaCl / 20% glycerol. Active fractions were combined and 
loaded directly on a hydroxylapatite column equilibrated with 
50 mM KPi / 0.8 M NaCl / 20% glycerol. After washing with 
this starting buffer and three bed volumes of 0.2 M KPi / 20% 
glycerol, the enzyme was eluted with a single step of 0.5 M 
KPi / 20% glycerol. The active fractions were dialyzed into 
storage buffer (0.5 M KPi / 50% glycerol) and kept at -20°C.
DNA topoisomerase assay:
Standard DNA topoisomerase I relaxation assay: Standard
DNA topoisomerase I activity was measured by the extent of 
relaxation of supercoiled pUC19 DNA as described by Lazarus et
18
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al. (34) . One unit of relaxing activity removes 50% of the 
supercoils from the substrate in 30 minutes at 30°C.
Relaxation of positively supercoiled DNA assay: Relaxed
pUC19 DNA was generated by treatment with nuclear DNA 
topoisomerase I under standard assay conditions and recovered 
by phenol extraction and ethanol precipitation. Ethidium 
bromide (4 jug/ml) was added to the relaxed pUC19 DNA to 
generate the positively supercoiled substrate for DNA 
topoisomerases. After the 30 min incubation, the reaction was 
stopped by 0.1 M EDTA and the ethidium bromide was removed by 
phenol extraction. The removal of the ethidium bromide from 
the relaxed DNA generates negatively supercoiled DNA. The 
conversion of the relaxed pUC19 DNA into the negatively 
supercoiled DNA indicates the relaxation of the positively 
supercoiled DNA by DNA topoisomerase.
DNA topoisomerase II assay: P4 unknotting assay was used 
to measure DNA topoisomerase II activity as described (73). 
One unit of activity converts 50% of the knotted DNA into 
unknotted monomer at 30°C in 30 min.
PCR amplification:
The sample contains 10 n 1 of 5X Taq buffer (83 mM of 
(NH4)2S04 , 3 3 5 mM of Tris-HCl (pH 8.8), 33.5 mM of MgCl2, 50 mM 
of J3-mercaptoethanol, 850 /il/ml of bovine serum albumin, and
19
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34 fiM of EDTA) , 3 jil of 25 mM each dNTP, 25 pmol each of
oligonucleotide primer, 5 /xl of DMSO, and 250 ng of template
DNA in a final volume of 50 /xl. After addition of 5 units of
Tag polymerase and 25 /zl of paraffin oil, the samples were
placed in an automatic thermocycler and incubated at 94°C for 
6 minutes, 28 cycles of 94°C for 30 seconds, 53°C for 30 
seconds, and 65°C for 2 minutes, and a final extension at 65°C 
for 7 minutes. The amplified samples were kept at 4°C until 
further analysis.
Uniquely end-labelled DNA substrate:
Using PUC19 plasmid DNA as substrate; Plasmid pUC19 was 
linearized with Eco RI and radiolabeled at the 5' end using T4 
polynucleotide kinase and [gamma-32P]ATP, followed by Hindlll 
restriction digestion to generate a substrate with only one 
strand radiolabeled.
Using PCR amplified bovine mitochondrial DNA as substrate; 
One primer was radiolabeled at the 5' end using T4 
polynucleotide kinase and [gamma-32P]ATP. The PCR
amplification protocol described above was employed with 10 
pmoles of each primer.
20
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DNA cleavage assay;
Uniquely end-labelled DNA substrate (5 ng) was incubated 
with DNA topoisomerase I (40 to 200 units) at 37°C for 15 
minutes in standard topoisomerase assay condition in the 
presence of 25 pM. of camptothecin unless otherwise noted. The 
reaction was stopped with addition of SDS (final concentration
0.5%) and digested with proteinase K (final concentration 0.5 
mg/ml) at 55°C for at least 30 minutes. An equal volume of TE 
saturated phenol was added to extract the protein. For 
separation on agarose gel electrophoresis (2% agarose, 60 V, 
5 hours) , 3 fil of alkaline stop solution was added. For
separation by denaturing PAGE (6% or 8% polyacrylamide, 7.5 M 
urea, 250 V, 4 hours), 20 pi of sequencing stop solution was 
added. The gel was dried under vacuum and analyzed by 
autoradiography.
DNA cleavage with exonuclease III degradation assay;
This protocol is the same as the DNA cleavage assay except 
for the addition of exonuclease III (65 U, 37°C for 30 
minutes) before proteinase K digestion. Uniquely end-labelled 
PCR amplified DNA was used as substrate and the assay products 
were separated on denaturing PAGE.
21
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DNA cleavage with Klenow extension assay:
The standard DNA cleavage assay was performed with non­
radiolabeled DNA substrate. Klenow DNA polymerase (1 Unit) 
and [a-32P]dCTP (2 /iCi) was added and incubated at 37°C for 3 
minutes before proteinase K digestion. The assay products 
were separated on denaturing PAGE.
DNA cleavage with T4 polynucleotide kinase phosphorylation 
assay:
Standard DNA cleavage assay was performed with non­
radiolabeled DNA substrate. T4 polynucleotide kinase (1 unit) 
and [gamma-32P]ATP (1.25 /iCi) was added and incubated at 37°C 
for 30 minutes before proteinase K digestion. The assay 
products were separated on denaturing PAGE.
PCR sequencing:
The reaction kit 11 fmol” from Promega was used. The 
reaction mixture A includes 50 ng of template DNA, 5 /il of 5X 
fmol buffer, 2 pmol of 32P labeled primer, 1 /il of sequencing 
Taq in a total volume of 17 /il. Four /il of mixture A was 
added to 1 /il each of dNTP/ddNTP. The samples were cycled as 
follow: 95°C for 2 min, 30 cycles of 95°C for 30 sec, 42°C for 
30 sec, and 70°C for 1 min. Five /il of sequencing stop was
22
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added and kept at 4°C. The samples were heated at 95°C for 5 
min immediately before loading to a sequencing gel.
Nick-translation of PPC19 DNA with fa-32PldATP or ra-32P1dCTP:
The pUC19 DNA was nick-translated using the 
nick-translation kit purchased from GIBCO BRL. Radiolabeled 
DNA was recovered by ethanol precipitation. The DNA was 
dissolved in TE and stored at -20°C.
Phosphorvl transfer assay:
The procedure followed was essentially that of Chow et al. 
(24) . Nick-translated pUC19 DNA (100 ng) was the substrate in 
the topoisomerase assay. One to two hundred units of 
topoisomerase were added to a final incubation mixture of 200 
jLtl • After 30 minutes at 30°C, an equal volume of 20% 
trichloroacetic acid was added, the precipitate was collected 
by centrifugation and washed twice with ice cold acetone. 
Forty fil of DNase I (0.1 mg/ml in topoisomerase assay buffer 
containing 5 mM CaCl2) was added and incubated for 30 minutes 
at 37°C. The reaction was stopped by the addition of an equal 
volume of SDS-polyacrylamide gel loading buffer. The samples 
were boiled for 3 minutes and applied to a 10% discontinuous, 
SDS-polyacrylamide gel.
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Thin laver chromatography for phosphoamino acids analvsia;
This procedure basically followed the phosphoryl transfer 
assay. The solution was dried under vacuum after DNase I 
digestion and digested at 110°C in 5.6 N HC1 sealed under 
nitrogen gas. The samples were dried again and separated on 
a silica gel TLC plate. The solvent mixture was Ethanol : 
Butanol : NH3 : H20 = 4 : 1 : 2 : 3 (v/v/v/v) . After
development of the plate for 5 hours at room temperature, the 
hydrolyzed products were visualized by ninhydrin and the 
phosphorylated amino acids were visualized by autoradiography. 
Autoradiography was performed for a proper length of time at - 
70°C using an intensifying screen.
Southern Hybridization:
The DNA samples in the agarose gel were transferred to a 
nylon membrane using a posiblot apparatus under 75 mmHg for 45 
to 60 min. The DNA was UV linked to the membrane by using a 
Stratalinker at 120,000 /iJ/cm2 for 30 sec. The membrane was 
prehybridized in 5X SSPE at 42°C for 1 hour followed by an 
overnight hybridization at the same temperature in 0.5% SDS, 
5X SSC, 5X Denhardt solution, 0.1 mg/ml salmon sperm DNA, 50% 
deionized formamide, and 25 to 50 ng/ml probe DNA. The 
membrane was washed as follows before exposure to an X-ray 
film: 30 min twice in 2X SSPE/0.1% SDS, 30 min twice in 0.2X 
SSPE/0.1% SDS, and 1 min once in 2X SSPE. Autoradiography was
24
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performed at -70°C using an intensifying screen.
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Chapter III. RESULTS
A. Mitochondrial DNA topoisomerase I
1. Purification of the enzvme
The type I mitochondrial DNA topoisomerase was purified 
from bovine liver by a procedure which was an adaptation of 
the previously published method for purification from calf 
thymus (34). The procedure was modified because mitochondria 
in bovine liver contain more enzymes and proteins than those 
in the thymus in order to support the detoxification function 
of the liver. Higher protease activity has also been observed 
in the liver (74). In order to minimize proteolysis and to 
avoid the nonspecific aggregation of proteins, a modified 
procedure for purifying DNA topoisomerases was developed.
The mitochondrial DNA topoisomerase I has been shown to be 
a 78,000 dalton protein (p78) (34). A 63,000 dalton protein 
(p63) was constantly copurified with the topoisomerase I from 
the previous preparation procedure (34). It has been shown 
that the p78 and p63 form a one to one complex under 
conditions of high salt (0.3 M KCl), whereas the complex 
dissociates at a lower salt concentration (0.1 M KCl) (75).
26
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As demonstrated by Chow et. al. (24) using a phosphoryl
transfer assay, DNA topoisomerases are the only proteins
phosphorylated when radiolabeled DNA is used as a substrate. 
These enzymes form a covalent enzyme-substrate complex, termed 
a "cleavable complex". Degradation by DNase I of
[32P]-radiolabeled DNA of the enzyme-substrate complex results 
in a radiolabeled enzyme. Figure 1 shows the result of a 
phosphoryl transfer assay using the mitochondrial DNA 
topoisomerase I purified from calf thymus using the previously 
published procedure (34). A radiolabeled p78 was seen in lane 
2, which contained the copurified p63 visualized by silver 
stain in lane 1. Due to the low yield of the enzyme, the p78 
was not visible by the silver stain.
To verify whether the p63 is the mitochondrial DNA
topoisomerase I or not, an immunoblot experiment using 
antibodies against nuclear enzyme was conducted. A slight 
cross-reactivity with antibody raised against nuclear DNA 
topoisomerase I was seen in the very faint band at the 78,000 
dalton position (lane d in Figure 2) of the immunoblot 
indicating the similarity of the structure of the 
mitochondrial and nuclear enzymes. The p63 protein did not 
cross react with the anti-nuclear topoisomerase I antibody. 
Hence, the p63 is not a mitochondrial DNA topoisomerase I and 
does not possess the DNA relaxation activity.
Based on the fact that p63 dissociates from p78 at low
27
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Figure 1. A result of a phosphoryl transfer experiment. Lane 
1, silver stained result of mixture of p63 and 
p78; lanes 2 through 4, results of phosphoryl 
transfer experiment; lane 2, treatment of p63 and 
p78; lane 3, plus BSA but no enzyme added; lane 4, 
treatment of nuclear DNA topoisomerase I. The 
number on the left indicates the molecular weight 
of the protein standard used.
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Figure 2. A result of immunobloting with anti-nuclear DNA 
topoisomerase I antibody. Lanes a through c, the 
silver stained result of the SDS-PAGE of the 
samples. Lanes d through f, the visualization of 
the immunoblot with rabbit anti-nuclear DNA 
topoisomerase I antibody. Lanes a and d, a 
fraction containing the mitochondrial p78; lanes b 
and e, purified p63; lanes c and f, nuclear DNA 
topoisomerase I.
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salt concentrations, the purification procedure for the 
mitochondrial topoisomerase I was modified. The detailed 
protocol is listed in Appendix II and is briefly summarized 
below. The bovine liver was ground and homogenized in 
mitochondrial isolation buffer (MIB) and a crude mitochondrial 
suspension was collected by differential centrifugation. The 
crude mitochondria were further purified by sucrose gradient 
ultracentrifugation. The purified mitochondria were treated 
with digitonin to strip off the outer mitochondrial membrane, 
thereby eliminating residual cytoplasmic contaminants.
In the previously published procedure of isolation from 
calf thymus, the mitochondrial enzyme was extracted from the 
fractured membranes after the cycles of freezing and thawing 
of the mitoplast at high salt concentration. This step is 
omitted in this modified protocol and is replaced with direct 
lysis of the mitoplasts by addition of the non-ionic 
detergent, Nonidet P40, at low salt concentration (0.1 M KCl) 
so as to maintain interactions between the mitochondrial DNA 
(mtDNA) and mtDNA binding proteins. After collecting the 
mtDNA-protein complexes by ultracentrifugation, the DNA 
topoisomerase I was extracted from the complex with a high 
ionic strength buffer (1.0 M KCl). No DNA topoisomerase I 
activity was detected in the 0.1 M KCl supernatant. The 1.0 
M KCl enzyme extract was then chromatographed on 
phosphocellulose, hydroxylapatite and double-stranded DNA 
cellulose columns, sequentially. For details see Appendix II.
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The purity of the mitochondrial preparation was assessed by 
the ratio of DNA polymerase gamma (the mitochondrial matrix 
enzyme responsible for mtDNA replication) to the DNA 
polymerase alpha (the nuclear polymerase responsible for 
chromosomal DNA replication). A ratio of at least 30 : 1 
serves as an indicator of mitochondrial origin (33, 34). A
ratio of 69 : 1 was obtained in the 1.0 M enzyme extract
fraction, indicating the mitochondrial origin of the purified 
enzyme.
The change in isolation procedure yielded a highly 
purified mitochondrial DNA topoisomerase I with a longer 
stability. Figure 3 shows the result of a silver stain of the 
purified enzyme on the SDS-PAGE. A single band above the BSA 
standard was seen on the gel in lane e, which consisted of the 
purified mitochondrial topoisomerase I eluted from the double 
stranded DNA cellulose column. The lack of the p63 in 
SDS-PAGE is evidence of the purity of the mitochondrial
topoisomerase I resulting from the improved procedure.
2. Catalytic properties of the enzvme
The optimal reaction conditions for the mitochondrial 
enzyme were investigated in the hope of distinguishing it from 
the nuclear enzyme. Figure 4 shows the effect of pH,
temperature and concentration of KCl on the mitochondrial DNA 
topoisomerase I relaxation activity. Figure 4A indicates pH
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Figure 3. The result of a silver stain of the purified
mitochondrial DNA topoisomerase I on the SDS-PAGE. 
Lane a, a fraction containing purified bovine liver 
mitochondrial DNA topoisomerase I from a double­
stranded DNA cellulose column. Lane b, a fraction 
without enzyme activity from a double-stranded DNA 
cellulose column. Lane c, combined active fractions 
from a hydroxylapatite column. Lane d, combined 
active fractions from a phosphocellulose column. 
Lane e, high salt extract, S2 (see Appendix II). 
Lanes f and g, bovine serum albumin. Lane h, high 
molecular weight SDS-PAGE standard.
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Figure 4. The effect of pH, temperature, and concentration 
of KC1 on mitochondrial DNA topoisomerase I 
relaxation activity. Panel A shows pH effects, 
panel B shows temperature effects, and panel C shows 
effects of KC1 concentration. The results represent 
the average of five or six assays. The standard 40 
mM Tris-HCl assay buffer (pH = 7.0) was used in all 
assays except otherwise noted.
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7 as being the optimal buffering condition for the relaxation 
activity. Figure 4B shows that the optimal reaction 
temperature is 37°C. Figure 4C suggests that the maximal 
relaxation activity of the mitochondrial DNA topoisomerase I 
is found at 200 mM KC1. These results are very similar to 
those for the nuclear DNA topoisomerase I (72).
Earlier studies of nuclear DNA topoisomerase I showed that 
magnesium ions are not essential for the enzymatic activity 
but will stimulate the enzyme activity (18). These same
studies also showed that nuclear DNA topoisomerase I can use 
any cation to replace monovalent ions. Therefore, the effect 
of divalent ions on the mitochondrial enzyme was studied. 
Figure 5 shows the stimulation of the mitochondrial enzyme 
activity by both magnesium and calcium ions at a concentration 
of 2.5 mM. The results also indicated that the enzyme can use 
any cation as a cofactor; either monovalent ions (K+ or Na+) 
or divalent ions (Mg2+ or Ca2+) alone could produce the
relaxation activity while in the absence of any cations there 
was no enzyme activity. Hence, there is no significant
difference in the catalytic properties of mitochondrial and 
nuclear enzymes with respect to cation requirements.
A further approach to characterize the mitochondrial
enzyme is to determine its kinetic properties, the maximal 
velocity (V,,̂ ) and the Michaelis constant, K,,,. Analysis of 
the kinetic data was often complicated by the fact that a
34
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Figure 5. The effect of divalent ions on the relaxation
activity of the mitochondrial DNA topoisomerase I. 
Panel A shows the effect of CaCl2 on the enzyme 
activity. Panel B shows the effect of MgCl2 on 
the enzyme activity. The same concentrations of 
the divalent ions were added to the same lane in 
both panels and no monovalent ions were added in 
all samples. Mitochondrial DNA topoisomerase I 
was added to all but the control samples. Lanes a 
and b, pUC19 DNA only as control. Lanes c and d, 
no divalent ions added. Lanes e through t, the 
duplicate results of addition of 2.5, 5, 7.5, 10, 
15, 20, 25, and 30 mM of divalent ions, 
respectively. I, supercoiled pUC19 DNA. Ir, 
relatively relaxed pUC19 DNA. I0 and II, completely 
relaxed and nicked pUC19 DNA, respectively.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
35
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
sizable fraction of the starting supercoiled DNA had to be 
enzymatically relaxed before the relaxed DNA could be detected 
by staining with ethidium bromide, which made early time 
points (before 10 minutes) difficult to obtain. A new 
approach using Southern hybridization with a radiolabeled 
pUC19 DNA probe to detect small amounts of relaxed DNA allowed 
determinations at very early time points. Figure 6 shows an 
example of this experiment. Using this method, the relaxed 
DNA could be detected at three or four minutes after the 
incubation with the enzyme as compared to 10 or 15 minutes of 
the normal assay. The intensities of the bands were scanned 
by laser densitometry and analyzed with the aid of a computer 
program which allowed quantification of the amounts of relaxed 
and substrate DNA at each given time points. Then, the amount 
of the product generated could be calculated by multiplying 
the total substrate used with the percentage of relaxed DNA 
formed.
The reaction rate is equivalent to the formation of the 
product from substrate under assumptions that the reverse 
reaction between the enzyme and the product is negligible and 
a rapid equilibrium between the substrate and the enzyme 
exists. Hence, the reaction rate can be derived by dividing 
the concentration of the product by the length of time of the 
assay. Under the same assay conditions, the initial reaction 
rates were obtained at various substrate concentrations for 
both nuclear and mitochondrial enzymes. A Lineweaver-Burk
36
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Figure 6. An autoradiograph of a southern hybridization of 
mitochondrial DNA topoisomerase I relaxation 
assay. The guantity of pUC19 DNA used is indicated 
on the top of each set of lanes. Lanes labeled 0 
has only the pUC19 DNA. Lanes labeled 3' and 4' are 
relaxation reactions for 3 and 4 minutes, 
respectively.
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plot was used to determine the V,^ and K,,, from the obtained 
data. Figure 7 is an example of this plot and the summarized 
results for mitochondrial and nuclear DNA topoisomerase I are 
shown in Table I. As seen in Table I, the of the
mitochondrial enzyme is 132.1 pM/min, which is approximately 
4 times larger than that of the nuclear enzyme. Also, the K,,, 
of the mitochondrial enzyme is 2.36 nM, which is more than 
five times over that of the nuclear enzyme. These results 
suggest a higher affinity for DNA substrate by nuclear enzyme. 
However, further studies are needed to verify these 
differences in V,,̂  and K,,, because the data obtained for the 
nuclear enzyme reflects a single determination.
3. Requirement for and effect of high energy carriers on 
enzyme activity
Although no ATP is required for the activity of type I DNA 
topoisomerases, ATP has been shown to inhibit the enzyme (76) . 
Since mitochondria are generators of the high energy carriers 
in cells, it is reasonable to assume that the level and 
activity of the mitochondrial enzymes is controlled by the 
concentration of high energy carriers. Hence, the effect of 
ATP, ADP, AMP, and NAD+ on the mitochondrial topoisomerase I 
was investigated. It was found that both ATP and ADP, at a 
concentration lower than 1 mM, have no effect on the enzyme 
activity (Figure 8), while almost 50% reduction in enzyme 
activity was seen at both 2 mM of ATP and 2 mM of ADP. A
38
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Figure 7. A Lineweaver-Burk plot of the mitochondrial DNA
topoisomerase I kinetic result.
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Table I. The kinetic constants of type I DMA topoisomerases
V,™ (pM/min) K™ (nM)
Mitochondrial DNA 
topoisomerase I




a, Average value of three trials, r2 = 0.9868.
b, Value from one trial, r2 = 0.9744.
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Figure 8. The effect of ATP and ADP on the relaxation
activity of the mitochondrial DNA topoisomerase I. 
Panel A shows the effect of ATP on the enzyme 
activity. Panel B shows the effect of ADP on the 
enzyme activity. The same concentrations of the 
ATP and ADP were added to the same lane in both 
panels and mitochondrial DNA topoisomerase I was 
added to all but the control samples. Lanes 
a through c, pUC19 DNA only as negative controls. 
Lanes d through f, plus enzyme only as positive 
controls. Lanes g through u, the triplicate results 
of addition of 0.25, 0.5, 1, 2, and 4 mM of ATP or 
ADP, respectively. I, supercoiled pUC19 DNA. Ir, 
relatively relaxed pUC19 DNA. I0 and II, completely 
relaxed and nicked pUC19 DNA, respectively.
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complete inhibitory effect was seen at 4 mM of both ATP and 
ADP. Neither AMP nor NAD+ had an inhibitory effect on the 
mitochondrial enzyme up to a concentration of 4 mM (data not 
shown). These results are similar to those of nuclear enzymes 
(76) .
4. Antitumor drug effect on the enzvme activity
The activity of type I DNA topoisomerase isolated from 
bovine liver mitochondria is shown in Figure 9 to be inhibited 
by camptothecin, a plant alkaloid previously shown to target 
the nuclear type I topoisomerase in mammalian cells (48).
In Figure 9, the effect of camptothecin on the DNA 
topoisomerase I relaxation activity is seen. Shown in Figure 
9A, in the absence of this drug, approximately two units of 
mitochondrial DNA topoisomerase I activity can convert almost 
all of the substrate DNA from the negative supercoils into the 
relaxed form (lanes b and c); however, the extent of 
relaxation is inhibited as the amount of camptothecin is 
increased. A substantial inhibition occurred at 2 /nM of 
camptothecin (lanes m and n) and essentially complete 
inhibition was effected by 25 /iM of camptothecin (lanes q and 
r). A similar profile was obtained with the nuclear enzyme 
(Figure 9B).
During replication and transcription, the movement of the
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Figure 9. The effect of the antitumor drug, camptothecin, on 
the DNA topoisomerase I relaxation activity. The 
antitumor drug was dissolved in DMSO and added to 
the assay mixture to make a final concentration of 
5% DMSO. Panel A is the result of the treatment of 
mitochondrial enzyme. Panel B is the result of 
the treatment of the nuclear enzyme. The same lanes 
in both panel have the same treatment. Lane a, 
pUC19 DNA only as a negative control. Lanes b and c, 
plus enzyme only as positive controls. Lane d, 
another positive control with enzyme and 5% of DMSO. 
Lane e through v, duplicate assay results from the 
addition of the following concentrations of 
camptothecin: 0.2, 0.4, 1, 2, 5, 10, 25, 50, 125 
lM, respectively. I, supercoiled pUC19 DNA. Ir, 
relatively relaxed pUC19 DNA. I0 and II, completely 
relaxed and nicked pUC19 DNA, respectively.
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replication and the transcription enzyme complexes along the 
DNA duplex can create significant torsional stress because of 
the accumulation of positive supercoils in front of the 
replication fork or transcription bubble. The need for 
release of this stress is evident and can be accomplished by 
the action of a type I topoisomerase. Therefore, the effect 
of camptothecin on the ability of the mitochondrial DNA 
topoisomerase I to relax positively supercoiled DNAs was 
examined. Figure 10 shows the results of this experiment. 
The positively supercoiled pUC19 DNA (lane a) was generated by 
intercalating the relaxed pUC19 DNA with ethidium bromide. If 
the mitochondrial DNA topoisomerase I was functioning as the 
nuclear enzyme, the positively supercoiled DNA would be 
relaxed by the enzyme. However, by removing the ethidium 
bromide from the enzyme-treated sample with phenol extraction, 
the DNA would become negatively supercoiled. This is seen in 
lane b. This relaxation activity is unaffected by 
concentrations of camptothecin lower than 10 /iM (lanes d-f) 
but is reduced as more camptothecin is added (lanes g-j).
The above result shows that it requires approximately 10 
to 20-fold more camptothecin to achieve the same level of 
inhibition in relaxing positive supercoils as it did to 
inhibit relaxation of negative supercoils (compare lanes i and 
j in Figure 10 with lanes m and n or o and p in Figure 9). 
The unexpected difference in the camptothecin concentration 
requirement for the mitochondrial enzyme prompted further
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Figure 10. The effect of camptothecin on the relaxation of 
positively supercoiled DNA by both mitochondrial 
and nuclear DNA topoisomerase I. Lanes a through 
j, mitochondrial enzyme-treated samples. Lanes k 
through t, nuclear enzyme-treated samples. Lanes 
a and k, relaxed pUC19 DNA only as a negative 
control. Lanes b and 1, plus enzyme only. Lanes 
c and m, plus enzyme and 5% DMSO as a positive 
control. Lanes d through j, plus camptothecin at 
at concentrations of 2.5, 5, 10, 20, 40, 80 and 
160 fiM, respectively. Lanes n through t, the same 
as lanes d through j. I, supercoiled pUC19 DNA. 
Ir, relatively relaxed pUC19 DNA. I0 and II, 
completely relaxed and nicked pUC19 DNA, 
respectively.
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investigation to study the effect of camptothecin on the 
ability of the nuclear DNA topoisomerase I to relax positively 
supercoiled DNA. Lanes n through t in Figure 10 show that the 
nuclear topoisomerase I exhibited the same level of 
sensitivity toward camptothecin as the mitochondrial enzyme 
did.
The antitumor drug m-AMSA, which has been shown to target 
the nuclear topoisomerase II, was also found to inhibit the 
mitochondrial type I DNA topoisomerase relaxation activity 
(Figure 11) . It can be seen that m-AMSA at 5 /xM (lanes i and 
j) begins to inhibit mitochondrial topoisomerase I relaxation 
activity, and at a concentration of 25 fiM the enzyme is 
completely inhibited (lanes o and p). Note that the pattern 
of inhibition caused by m-AMSA (Figure 11) is different from 
that of camptothecin (Figure 9). Since m-AMSA is known to 
intercalate into DNA, this inhibition could be due either to 
a direct inhibition or interaction with the mitochondrial 
enzyme or to the intercalation of the drug into the DNA which 
causes a change in the DNA conformation. The following two 
experiments were conducted in order to determine which 
mechanism causes the inhibitory effect of m-AMSA. They are 
the DNA cleavage assay and the relaxation of positively 
supercoiled DNA in the presence of m-AMSA.
The DNA topoisomerase-targeting antitumor drugs have been 
proven to stabilize the enzyme-substrate cleavable complex by
46
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Figure 11. The effect of type II DNA topoisomerase targeting 
antitumor drugs, m-AMSA, on mitochondrial DNA 
topoisomerase I relaxation activity. The m-AMSA 
was dissolved in DMSO and added to the assay 
mixture to make a final concentration of 5% DMSO. 
The result shows a decrease in enzyme activity as 
the concentration of m-AMSA increases. Lanes a 
and b are negative controls with pUC19 DNA only. 
Lanes c and d are positive controls with the 
enzyme only. Lanes e and f are positive controls 
with the enzyme and a final concentration of 5% 
DMSO. Lanes g through t are duplicate assay 
results in the following concentrations of m-AMSA: 
2.5, 5, 7.5, 10, 25, 50, 100 /iM, respectively.
I, supercoiled pUC19 DNA. Ir, relatively relaxed 
pUC19 DNA. I0 and II, completely relaxed and 
nicked pUC19 DNA, respectively.
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inhibiting the resealing ability of the enzymes (61). The 
direct interaction of DNA topoisomerases with the antitumor 
drugs should result in the trapping of an enzyme-substrate 
cleavable complex and subsequent degradation of the substrate 
DNA. Using a DNA substrate with only one end radiolabeled on 
one strand (uniquely end labeled), the degraded DNA fragments 
can be separated and observed on a denaturing gel. Figures 12 
and 13 show the results of cleavage assays affected by 
camptothecin and m-AMSA.
Using uniquely end labeled pUC19 DNA as substrate, the 
effect of camptothecin on both nuclear and mitochondrial 
topoisomerase I-induced cleavage is seen in Figure 12. No or 
very little DNA cleavage was seen without addition of 
camptothecin in both nuclear (lanes c through e) and 
mitochondrial topoisomerase I (lanes i through k) cleavage 
assays, while the addition of camptothecin greatly stimulated 
the cleavage of the DNA substrate (lanes f through h and 1 
through m). Figure 13 compares the effect of camptothecin and 
m-AMSA on the cleavage assay. Lanes c through f show that the 
lower strand of H-ORI (see definition in section 5) was 
cleaved by the mitochondrial topoisomerase I in the presence 
of camptothecin at concentrations ranging from 2.5 to 25 /liM. 
A similar profile would be expected if the inhibitory effect 
of m-AMSA was due to the trapping of the enzyme-DNA cleavable 
complex. As seen in lanes i through 1, the m-AMSA in 
concentrations between 2.5 to 25 fXi/l does not stimulate
48
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Figure 12. An autoradiograph showing the effects of
camptothecin on DNA cleavage by nuclear and 
mitochondrial DNA topoisomerase I. Linearized 
uniquely end-labeled pUC19 DNA was used as 
substrate. Lane a is a labelled DNA only. Lane b 
contains labelled DNA and 25 /iM camptothecin. 
Lanes c through e are the result of the assay using 
10, 20, and 40 units of nuclear DNA topoisomerase 
I without camptothecin. Lanes f through h are the 
same as lanes c through e with 25 juM camptothecin. 
Lanes i through k represent the results of the 
assay using 25, 50 and 75 units of mitochondrial 
DNA topoisomerase I without camptothecin. Lanes 1 
through n are the same as lanes i through k with 25 
/nM camptothecin.
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Figure 13. A DNA cleavage assay showing the DNA was cleaved 
in the presence of camptothecin but not mAMSA. 
Forty units of mitochondrial DNA topoisomerase I 
was used in all but control samples. The lower 
strand radiolabeled H-ORI was used as substrate. 
Lanes a, b, g, and h, amplified H-ORI DNA only. 
Lanes c, d, i, and j, with 2.5, 5, 10, and 25 yM. of 
camptothecin, respectively. Lanes e, f, k, and 1, 
with 2.5, 5, 10, 25 yM. of m-AMSA, respectively.
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cleavage of DNA by the mitochondrial enzyme. Since these 
concentrations of m-AMSA have been shown to completely inhibit 
mitochondrial DNA topoisomerase I relaxation activity (see 
Figure 11), this lack of cleavage indicates that the m-AMSA 
does not trap a cleavable complex intermediate during the 
reaction catalyzed by the mitochondrial enzyme.
To further support this conclusion, the effect of m-AMSA 
on the ability of the mitochondrial DNA topoisomerase I to 
relax positively supercoiled DNA was investigated. If the 
inhibition of relaxation of negatively supercoiled DNA by 
m-AMSA observed earlier was the result of an intercalation of 
the drug into the substrate DNA, the use of positively 
supercoiled DNA would decrease the availability of sites for 
drug intercalation, thereby decreasing the inhibitory effect 
of the m-AMSA. Figure 14 shows the inability of the m-AMSA to 
inhibit the relaxation of positively supercoiled DNA as the 
DNA substrate has already been intercalated by ethidium 
bromide. As in Figure 9, the relaxation of positively 
supercoiled DNA is indicated by the presence of negatively 
supercoiled DNA in the gel (lane b). In Figure 14 the 
addition of as much as 250 juM m-AMSA has no inhibitory effect 
of the production of negatively supercoiled DNA. Thus, in 
contrast to the results with negatively supercoiled DNA (see 
Figure 11), there is no inhibition of the relaxation of 
positively supercoiled DNA by m-AMSA. This result further 
indicates that the inhibition observed in Figure 11 is due to
51
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Figure 14. The effect of m-AMSA on the relaxation activity 
of positively supercoiled DNA by mitochondrial 
DNA topoisomerase I. Lane a, relaxed pUC19 DNA 
only as a negative control. Lane b, plus enzyme 
only as a positive control. Lanes c through g, 
with 12.5, 25, 50, 250 fiM of mAMSA, respectively. 
I, supercoiled pUC19 DNA. Ir, relatively relaxed 
pUC19 DNA. I0 and II, completely relaxed and 
nicked pUC19 DNA, respectively.
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the intercalation of m-AMSA and not due to a specific 
interaction of the drug with the mitochondrial DNA 
topoisomerase I.
The effect of the nonintercalator drug VM 26 which targets 
type II DNA topoisomerase was also investigated. No 
inhibitory effect on relaxation of negatively supercoiled DNA 
by this drug was seen up to concentrations of 50 /xM (data not 
shown). This result indicates that no contaminating type II 
DNA topoisomerase is present in the purified mitochondrial 
enzyme fraction.
5. Interaction of the enzyme with the substrate DNA
In order to understand how mitochondrial DNA topoisomerase 
I interconverts the topological structures of DNA and whether 
the mitochondrial enzyme interacts with its substrate DNA in 
the same way as the nuclear or bacterial enzyme, the 
interaction of the mitochondrial DNA topoisomerase I and its 
substrate DNA was investigated.
1.) Identification of the specific interaction sites
In addition to differentiating the direct or indirect 
effect of the antitumor drugs on DNA topoisomerases, the 
results of DNA cleavage assays also reveal whether 
mitochondrial DNA topoisomerase I reacts with the DNA
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substrate in a random fashion or at a specific site(s). The 
use of DNA substrates with only one radiolabeled end allows 
the identification of the cleaved DNA sites by 
autoradiography, since all fragments visualized contain the 
same end-terminal radiolabeled nucleotide. Distinctive 
patterns of the cleaved DNA would indicate that specific sites 
were cut by the enzyme, while a pattern of smeared DNA would 
suggest that the enzyme cleaved randomly. As seen in Figure 
12 and Figure 13, the purified mitochondrial enzyme-treated 
sample shows distinct cleaved DNA bands using two different 
DNA substrates, pUC19 DNA and H-ORI. This pattern indicates 
that the mitochondrial DNA topoisomerase I recognizes and 
cleaves the substrate DNA at specific sites in the same manner 
as nuclear enzyme.
Further examination of the cleavage patterns of DNA 
induced by the nuclear and mitochondrial topoisomerase I in 
the presence of camptothecin found that both the nuclear and 
mitochondrial enzymes cleave pUC19 DNA at almost identical 
sites (Figure 12) . All the bands present in the mitochondrial 
DNA topoisomerase I treated samples (lanes m and n) are also 
visible in the nuclear enzyme-treated samples (lanes f-h). 
There are several bands which, although present in both 
enzyme-treated samples, are significantly different in 
intensity, suggesting that there may be some preference for 
some sites by either topoisomerase. For example, bands 
labeled 1, 2, 3 and 4 in lane n have higher intensity than in
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lane f indicating a preference by the mitochondrial enzyme. 
Since the residual amount of uncleaved DNA at the origin is 
comparable in both lanes f and n, this result indicated that 
an equivalent amount of enzyme activity was present in both 
sample treatments.
The previous result suggested the possibility that the 
mitochondrial DNA topoisomerase I might prefer to act on 
certain DNA sequences and that this sequence preference might 
be different from that of the nuclear enzyme. Experiments 
were designed to search for preferential cleavage sites by 
mitochondrial DNA topoisomerase I. DNA sequences of the 
mitochondrial genome would be strong candidates for possible 
specific interactions with a mitochondrial type I DNA 
topoisomerase. DNA fragments from the mitochondrial genome 
were used as substrate DNA for a mitochondrial enzyme cleavage 
assay. Three regions of the 16.5 Kbp mitochondrial DNA were 
selected based on the involvement of the DNA topoisomerases 
with gene replication and transcription. Regions selected 
were the heavy and light strand origins of replication, and 
the transcription termination region located at the boundary 
of the 12 S ribosomal RNA and leucine tRNA genes.
In order to have enough DNA substrate for these 
investigation, the polymerase chain reaction was employed to 
generate the DNA substrate. Using the published bovine 
mitochondrial DNA sequences and a computer aided program "PCR
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Primer Designer”, three sets of DNA primers were selected from 
the respective regions mentioned above. The primers met the 
criteria of GC content between 40% to 60%, melting temperature 
between 75°C and 85°C, no more than 2 G or C at the 3' end and 
no secondary structure. Three fragments of DNA were amplified 
from these primer sets by a multiplex polymerase chain 
reaction taking place in a thermocycler. They are designated 
as H-ORI (heavy strand origin of replication), L-ORI (light 
strand origin of replication) and TERM (transcription 
termination region). Figure 15 shows the sequences of these 
primers and the length and regions being amplified.
Figures 16 - 18 show the results of DNA cleavage assays 
using these three amplified DNAs as substrates. With the 
H-ORI, the cleavage of the upper strand of this 797 bp region 
by both the nuclear and mitochondrial topoisomerases was 
essentially the same (Figure 16A, lanes b and c). Differences 
in the intensities of the higher molecular weight bands 
(labelled 1 and 2) and lower molecular weight bands (labeled 
3 - 5) reflect the differences in the activity of
topoisomerase used in these experiments (as judged by the 
amount of the residual undegraded, starting material). The 
nuclear enzyme was somewhat more active, resulting in a 
complete loss of starting substrate and production of small 
DNA degradation products.
Furthermore, in Figure 16B, the cleavage of the lower
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Figure 15. A representation of the locations of the PCR 
amplified DNA fragments on the bovine 
mitochondrial genome. Panel A is a list of the 
primer sequences used. Panel B is a simplified map 
of the mitochondrial DNA with the amplified DNA 
fragments indicated as different shaded boxes. The 
location and the length of the DNA fragments is 
also listed.
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Sequences of the primers used in amplification 
of bovine mitochondrial genome.
H-ORI Left: S’-AACC AGAGAAGGAGAAC AACTAACCTC-3 * 
Right: 5’-GCTCAAGATGCAGITAAGTCCAGCTA-3 ’
L-ORI Left: 5,-ACGACTCACGTATTCTACCACACTA-3, 
Right: S’-GAACAAGTCAGTTACCGAATCCTCC-S’
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Figure 16. The results of a DNA cleavage assay using amplified 
H-ORI DNA fragment as substrate. Panel A, upper 
strand radiolabelled. Panel B, lower strand 
radiolabelled. The same lanes in both panel have 
the same treatment. Lane a, DNA only. Lane b, 
plus 40 units of nuclear DNA topoisomerase I.
Lane c, plus 40 units of mitochondrial DNA 
topoisomerase I.
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strand of the H-ORI by both enzymes gave similar results. 
Here again, the slightly greater amount of nuclear enzyme 
results in higher intensity of smaller degradation products 
(labeled 5 and 6) and a lower intensity of high molecular 
weight bands (labeled 1 - 4). It should be noted that the 
patterns of the cleavage differ along the upper and lower 
strands of H-ORI (compare Figure 16A with Figure 16B). This 
result suggests that DNA topoisomerase I can recognize and 
cleave both DNA strands.
Figure 17 shows results of the DNA topoisomerase I 
cleavage of the L-ORI region. This 790 bp PCR-amplified 
substrate is also degraded by both the mitochondrial and 
nuclear enzymes in similar fashion. The results using upper 
strand L-ORI are shown in lanes a through c and the results 
using lower strand L-ORI are shown in lanes d through e. 
Again, there is a slightly greater amount of nuclear enzyme 
activity, hence a slightly greater intensity of lower 
molecular weight DNA fragments was seen in lane b compared to 
bands in lane c. However, the high intensity of the band 
labeled 1 in the mitochondrial enzyme treated sample in lane 
f suggests that this site may be a preferred site for cleavage 
by the mitochondrial enzyme.
The cleavage of the upper and lower strands of the TERM 
region is shown in Figures 18A and 18B, respectively. An 
intense band indicated by an arrow in Figure 18A is seen in
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Figure 17. The results of a DNA cleavage assay using amplified 
L-ORI DNA fragment as substrate. Lanes a through 
c, upper strand radiolabelled. Lanes d through 
f, lower strand radiolabelled. Lanes a and d,
DNA only. Lanes b and e, plus 40 units of 
nuclear DNA topoisomerase I. Lanes c and f, plus 
40 units of mitochondrial DNA topoisomerase I.
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Figure 18. The results of a DNA cleavage assay using amplified 
TERM DNA fragment as substrate. Panel A, upper 
strand radiolabelled. Lanes a, DNA only. Lanes 
b and c, plus 40 units and 8 units of nuclear 
enzyme. Lanes d and e, plus 40 units and 8 units 
of mitochondrial enzyme. Panel B, lower strand 
radiolabelled. Lanes a and b, DNA only. Lanes c 
and d, plus 40 units of nuclear enzyme. Lanes e 
and f, plus 40 units of mitochondrial enzyme. 
Panel C, lower strand radiolabelled and 
separation on a 12 % denaturing PAGE. Lanes a 
and b, DNA only. Lanes c and d, plus 80 units and 
40 units of nuclear enzyme. Lanes e and f, plus 
80 units and 40 units of mitochondrial enzyme.
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the lanes treated with nuclear DNA topoisomerase I. Due to 
the small size (about 100 nucleotides) of this band, the band 
intensity could be caused by the higher amount of nuclear 
enzymes in the sample instead of a strong nuclear enzyme 
preference. On the other hand, comparing lanes e and f to 
lanes c and d in Figure 18B indicates that at least 2 
fragments (labeled 1 and 2) are clearly produced in much 
greater amounts by the mitochondrial DNA topoisomerase I. 
Since the level of starting substrate remaining is essentially 
the same in these lanes, suggesting that the amounts of enzyme 
activities are closely equivalent, this increased proportion 
of bands 1 and 2 probably reflects a stronger preference of 
the mitochondrial enzyme for these sites. Further study 
revealed that more nuclear DNA topoisomerase I was required in 
order to produce equivalent amounts of these bands. Figure 
18C shows these results; the DNA fragments were separated in 
a higher percentage of polyacrylamide gel to achieve a better 
resolution.
In most cases both the mitochondrial and nuclear enzymes 
recognize the same DNA sequences for cleavage. However, 
several preferred cleavage sequences by either enzyme were 
observed from these DNA cleavage assay results. Further 
investigations on these sequences were conducted in order to 
understand whether a consensus sequence was recognized by 
these enzymes and what sequences these enzymes preferred. 
These results will be presented and discussed in section 3.)
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Studies of sequence specificity and conformation of preferred 
DNA substrates.
2.) Verification and characterization of the transient 
covalent linkage
The translocation of the radiolabeled phosphate group from 
the DNA substrate to the mitochondrial DNA topoisomerase I in 
the phosphoryl transfer assay (see Figure 1) proves that the 
mitochondrial enzyme forms a transient covalent linkage to its 
substrate as demonstrated in the cases of other type I DNA 
topoisomerases. The polarity of the DNA strand which linked 
to DNA topoisomerase I was proven to be at the 3' end of the 
DNA break for the eukaryotic enzyme and at the 5' end of the 
DNA break for the prokaryotic enzyme (21). It has been shown 
that prokaryotic DNA topoisomerase I from E. coli and M. 
luteus cleaves substrate DNA to yield a 3' hydroxyl and a 5' 
phosphate group to which the enzyme becomes linked. On the 
other hand, eukaryotic DNA topoisomerase I produces a 5' 
hydroxyl and a 3' phosphate group to which it becomes 
covalently attached. In all cases, a tyrosine residue in the 
active site of the enzymes is involved in the covalent 
linkage.
The amino acid residue in the mitochondrial topoisomerase 
I which formed this covalent linkage to the substrate DNA was 
determined. After incubating DNA topoisomerases with uniformly
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32P-radiolabeled pUC19 DNA to allow covalent linkage, 
degrading the DNA with DNase I, and digesting the 
topoisomerases in 5.6 M HC1 at 110°C, the amino acids 
liberated were separated by thin layer chromatography (TLC). 
Figure 19 shows the result of this experiment. Panel A shows 
the visualization of the phosphoamino acids with ninhydrin. 
Panel B is the autoradiograph of the same TLC plate. It is 
evident that radiolabeled phosphotyrosine is observed in both 
the mitochondrial enzyme (lanes c and d) and nuclear enzyme 
(lanes e and f) treated samples. The material migrating 
slightly ahead of the phosphotyrosine is the incompletely 
degraded oligonucleotide as shown in comparison to lane b 
which contains labeled pUC19 DNA without the treatment of 
DNase I and HCl. Therefore, like nuclear DNA topoisomerase I, 
the mitochondrial enzyme has become linked to DNA through a 
phosphotyrosine covalent bond.
After establishing a phosphotyrosyl linkage between the 
mitochondrial DNA topoisomerase I and its substrate DNA, the 
question of whether the mitochondrial DNA topoisomerase I is 
covalently attached to the 3' end or 5' end of the DNA 
cleavage site was investigated. A common experiment utilizes 
potassium-SDS precipitation of the DNA topoisomerase-DNA 
complex with 3' or 5' labeled DNA to determine to which end of 
the cleaved DNA the mitochondrial enzyme was linked. Using 
this approach, a large amount of enzyme is required to react 
with substrate DNA in order to yield a significant signal to
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Figure 19. Analysis of phosphoamino acids involved in the
covalent linkage between DNA topoisomerase I and 
the substrate DNA by thin layer chromatography. 
Panel A, visualization of phosphoamino acids by 
ninhydrin. Panel B, autoradiography of the same 
TLC plate. Lane a, nonhydrolyzed mitochondrial 
DNA topoisomerase I only. Lane b, untreated DNA. 
Lanes c and d, hydrolyzed mitochondrial DNA 
topoisomerase I. Lanes e and f, hydrolyzed 
nuclear DNA topoisomerase I. Lanes g, h, and i, 
200 nmoles of phosphoserine, phosphothreonine, 
and phosphotyrosine, respectively.
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noise ratio. Ambiguous results were obtained with this method 
due to the limited amount of mitochondrial DNA topoisomerase 
I could be used. However, using Exonuclease III in the DNA 
cleavage assay this question was answered.
Exonuclease III (Exo III) is a 3' -> 5' exonuclease
producing 5' mononucleotides and is specific for dsDNA which 
has a free 3' hydroxyl terminus at blunt or 5' overhang ends 
or at a nick. As the diagram in Figure 20 shows, if the 3' 
end of the DNA break is free of enzyme attachment, the Exo III 
will degrade the DNA strand. This would alter the migration 
rate of the topoisomerase-generated cleavage products upon gel 
electrophoresis. If the 3' end of the DNA break is blocked by 
the enzyme, no change in the migration rate of topoisomerase 
cleavage products would occur. The starting DNA band which 
has not been cleaved by DNA topoisomerases would disappear due 
to degradation by Exo III.
Since the catalytic properties and characteristics of the 
mitochondrial DNA topoisomerase I resembled the nuclear enzyme 
in many ways judging from data gathered so far, the result of 
the Exo III / Cleavage assay was surprising. In the samples 
treated with the mitochondrial enzyme, evidence of a free 3' 
end at the DNA cleavage site was seen (Figure 21) suggesting 
that the mitochondrial topoisomerase I becomes linked to the 
5' phosphate group. Panel A in Figure 21 shows the result of 
a regular DNA cleavage assay using L-ORI with the upper strand
66
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Figure 20. A schematic diagram of Exo III / cleavage 
which indicates expected results of a 3' 
linkage to DNA topoisomerase I.
assay 
or 5'
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Figure 21. The results of an Exo III / cleavage assay to 
determine the linkage of DNA to the mitochondrial 
enzyme. Panel A, regular DNA cleavage assay. 
Panel B, DNA cleavage assay with additional 
treatment of exonuclease III. Lanes a and b, DNA 
only. Lanes c and d, plus 40 units of nuclear 
enzyme. Lanes e and f, plus 40 units of 
mitochondrial enzyme. The shortening of the 
cleaved DNA fragment, which migrated faster in 
the denaturing PAGE is caused by the free 3' end 
being degraded by the exonuclease III.
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uniquely end-labeled. Lanes a and b are control DNA samples 
without any DNA topoisomerase added. Lanes c and d show 
camptothecin stimulated cleavage of the substrate DNA by the 
nuclear DNA topoisomerase I. Lanes e and f show a similar 
cleavage pattern using the mitochondrial DNA topoisomerase I. 
Panel B in Figure 21 shows the result with the treatment of 
Exo III.
In both panels, the DNA cleavage pattern of the samples 
with nuclear enzyme added (lanes c and d) closely resemble one 
another except for the disappearance of most of the uncleaved 
substrate. Since the nuclear DNA topoisomerase I is known to 
become linked to a 3' phosphate when it cleaves DNA (21), the 
nuclear enzyme is expected to block the 3' ends of cleaved 
fragments, protecting them from Exo III degradation. Thus it 
is expected that the migration rates of nuclear topoisomerase 
cleavage fragments should be the same with or without Exo III 
treatment. If the mitochondrial enzyme acts by the same 
mechanism, then the migration rates of those cleavage 
fragments should also be the same with or without Exo III. 
However, the comparison of lanes e and f in both panels shows 
that the Exo III treatment has altered the mobility of many of 
the bands generated by the mitochondrial DNA topoisomerase I. 
These data suggest that the mitochondrial DNA topoisomerase I 
is linked to the phosphate at the 5' end of the cleavage site 
which would leave a free 3' hydroxyl group on the other side 
of the break.
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However, one could argue that the free 3' end of the 
cleavage sites caused by the mitochondrial DNA topoisomerase 
I is due to the fact that the mitochondrial enzyme does not 
form a covalent linkage as strong as the nuclear enzyme and 
that the Exo III or that the reaction conditions for the Exo 
III were able to prevent the mitochondrial enzyme from 
permanently attaching to the DNA. Two other experiments were 
designed to test these results. These two assays are 
variations of the Exo III / Cleavage assay using T4 
polynucleotide kinase (T4 PNK) and E. Coli. DNA polymerase 
Klenow fragment. After the DNA cleavage assay, the
enzyme-substrate complex was subjected to either T4 PNK with 
[gamma-32P]ATP or the Klenow DNA polymerase with [a-32P]dCTP 
treatment. Using T4 PNK, which only phosphorylates the 5' 
end of DNA strand, a blockage at the 5' end will be verified 
if no or little DNA is radiolabeled. By the same token, 
Klenow DNA polymerase, which has a 5' -> 3' polymerase
activity and a 3' -> 5' exonuclease activity, could assess 
free or blocked 3' ends.
Figure 22 shows a diagram of the reasoning behind this 
experimental design. Shown in the left panel, the Klenow DNA 
polymerase will incorporate less radioactive precursor into 
DNA fragments cleaved by the nuclear DNA topoisomerases I, 
which is covalently bound to the 3' end of each fragment, than 
those cleaved by the mitochondrial enzyme, which has been 
suggested to form a 5' end covalent bond. For the T4 PNK
70
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 22. Schematic diagrams of the reasoning behind the
Klenow / cleavage assay and the T4 PNK / cleavage 
assay.
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/cleavage experiment, one would expect just the opposite 
result, with the nuclear enzyme yielding fragments that are 
labeled by T4 PNK and [gamma-32P] ATP because they have free 5' 
hydroxyl groups. If the mitochondrial enzyme is covalently 
attached to the 5' ends of these fragments then T4 PNK would 
not be able to label all the cleaved fragments except the ones 
at the 5'ends of each starting substrate DNA. This would 
result in smaller radiolabeled bands. The incorporation of 
radioactivity can be assessed both by scintillation counting 
of high molecular weight DNA and by autoradiography after gel 
electrophoresis. These results are presented in Figure 23 and 
Figure 24.
Figure 23 shows results of the T4 PNK / Cleavage assay. 
Panel A shows the autoradiograph of the separation of the 
radiolabeled DNA fragments by denaturing gel electrophoresis. 
Without DNA topoisomerase I treatment (lanes a through c), the 
only radiolabeled band is the substrate DNA. In the nuclear 
enzyme treated samples (lanes g through i), many radiolabeled 
DNA bands are seen and the majority of the radiolabeled bands 
are large DNA fragments, indicating free 5' ends on these DNA 
fragments. By contrast, in the mitochondrial enzyme treated 
samples (lanes j through 1), the radiolabeled bands are either 
the starting material or small DNA fragments which are the 
result of blocked 5'ends. Note in lanes d through f that
addition of camptothecin did not inhibit the incorporation 
activity of T4 PNK. Panel B shows the results of
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Figure 23. The results of a T4 PNK / cleavage assay to 
determine the linkage of DNA to the mitochondrial 
enzyme. Panel A shows the electrophoretic results 
of this assay. Lanes a, b and c, DNA only. Lanes 
d, e and f, DNA with 25 iM camptothecin. Lanes g, 
h and i, plus nuclear enzyme and 25 pH of 
camptothecin. Lanes j, k and 1, plus mitochondrial 
enzyme and 25 nM of camptothecin. Panel B shows 
the results by scintillation counting.
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B.





40 units 40 units
L-ORI 427.5 1377.3 567.2
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Figure 24. The results of a Klenow / cleavage assay to 
determine the linkage of DNA to the mitochondrial 
enzyme. Panel A shows the electrophoretic results 
of this assay. Lanes a, b and c, DNA only. Lanes 
d, e and f, DNA with 25 fiM camptothecin. Lanes g, 
h and i, plus nuclear enzyme and 25 fxM of 
camptothecin. Lanes j, k and 1, plus mitochondrial 
enzyme and 25 /xM of camptothecin. Panel B shows 
the results by scintillation counting.
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B.
Results of scintillation counting of Klenow /Cleavage assay





80 units 40 units 80 units 40 units
H-ORI 969.6 142.6 N.D. N.D. 1971.1
L-ORI 696.6 304.3 641.7 1511.7 1468.6
TERM 297.2 147.3 336.1 710.8 1122.0
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scintillation counting, which clearly indicates a low 
incorporation of radionucleotides in the mitochondrial treated 
samples. Both outcomes indicate a blockage of the 5' end of 
the DNA break by mitochondrial DNA topoisomerase I.
The results of the Klenow / Cleavage assay are given in 
Figure 24. Again, panel A is the autoradiograph of the gel 
electrophoresis and panel B shows the results of scintillation 
counting. As in the experiments with T4 PNK, no inhibitory 
effect by camptothecin of radioactive incorporation by Klenow 
DNA polymerase was seen (compare lanes d through f to lanes a 
through c). As expected in the nuclear enzyme-treated 
samples, no or very little DNA was radiolabeled due to the 
covalent linkage of the enzyme to the 3' ends of the DNA 
breaks. On the contrary, a smeared image was seen in the 
mitochondrial enzyme treated samples. Klenow DNA polymerase 
extended the mitochondrial enzyme-cleaved DNA into various 
lengths. These results further confirm that a free 3' 
hydroxyl group was generated by the mitochondrial enzyme.
Thus, the above evidence indicates that the mammalian 
mitochondrial type I DNA topoisomerase resembles the bacterial 
enzyme in its linkage to the 5' end of DNA break. This is the 
first verification that mitochondrial DNA topoisomerase I 
clearly differs from the nuclear enzyme and establishes the 
fact that mammalian mitochondria maintain their own DNA 
topoisomerases.
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3.) Studies of sequence specificity and the 
conformation of preferred DNA substrates
The fact that mitochondrial DNA topoisomerase I recognizes 
and cleaves DNA in a non-random fashion was presented earlier 
(Figure 12). The immediate question is, what kind of DNA 
sequences do the DNA topoisomerases recognize? To answer 
this, sequence analysis of mitochondrial and nuclear 
topoisomerase I cleavage sites was conducted by utilizing the 
dideoxy-sequencing technique. To investigate the sequences 
around the cleavage sites, the DNA substrates were PCR 
amplified from bovine mitochondrial DNA with one end-labeled 
primer and again used in the DNA topoisomerase cleavage assay. 
The same primer was used in four dideoxy PCR sequencing 
reactions in reagents provided by the commercially obtained 
"fmol kit" to generate four sets of varying lengths of 
oligonucleotides. The products of the sequencing reaction and 
the cleavage assay reactions were resolved side by side on a 
denaturing polyacrylamide sequencing gel. Figure 25 shows a 
typical autoradiographic example of one such gel. The arrows 
indicate the cleavage by DNA topoisomerase I between the two 
flanking nucleotides.
Using this process, seventy-nine cleavage sites were 
identified. Table II lists 20 nucleotides upstream and 
downstream from all of the cleavage sites. A detailed
78
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Figure 25. An autoradiographic example of DNA sequence
analysis of DNA cleavage sites. The four lanes 
designated A, G, C, and T are the dideoxy 
sequencing products. The lanes designated m are 
the mitochondrial enzyme-treated DNA cleavage 
assay products. The lanes designated n are the 
nuclear enzyme-treated DNA cleavage assay 
products. The arrows indicate the cleavage 
sites.
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Table II. List of all the cleavage sites with both 20 
upstream and downstream nucleotides. All sequences are listed 
from 5' to 3'. The space between the two sequences indicates 
the cleavage site.
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Table II. (Continued)
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examination showed no single recognizable nucleotide at both 
ends of cleavage and no consensus sequences. Therefore, 
several approaches were attempted to analyze the data. 
Analysis based on the absolute occurring frequency of each 
base suggests a prevalent T (43%, P = 0.01) at the 3' end of 
the DNA break. To determine any consensus sequences flanking 
the cleavage site, base compositions of the DNA fragments, 
which are 30.15% for A and T and 19.85% for G and C, were 
taken into account. A sequence was deduced by considering 
whether a residue occurred with higher observed base frequency 
than the expected base frequency at a certain position 
relative to the cleavage site. The resulting sequence is 
A N A  ( A / T ) ( A / T )  T T C G A T T T T A G  ( G / A )  ( A / G )  G T  * 
(A/G)ANNN(T/G)NTNNTGN(G/C)GGCCTA, where N is any nucleotide 
and the asterisk indicates the point of cleavage.
However, due to the difference in base compositions each 
base has different standard error. The standard error is 
derived from the expected frequency for a given sample size. 
It is calculated by taking the square root of the following 
equation: Expected frequency * ( 1 - Expected frequency) / 
sample size. Thus, the standard error for A and T would be 
V.  3015*(1-.3015)/79 = 0.0516 and the standard error for G and 
C would be V.1985*(1-.1985)/79 = 0.0449. The upper and lower 
bounds of a confidence interval (Cl) are computed by adding to 
and subtracting from the expected frequency the standard error 
times the appropriate value from the normal distribution. For
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a 90% Cl, the value is 1.645. For 95% and 99% CIs, the values 
are 1.96 and 2.757.
Figure 26 shows a plot of relative base frequency at all 
40 analyzed sites. The solid horizontal line is the expected 
relative frequency and the 90% confidence interval is plotted 
as dashed horizontal lines. When an observed frequency falls 
beyond the confidence interval, it is viewed as statistically 
different. This out of boundary frequency indicates that 
there is only a 10% chance that this difference between the 
observed and the expected relative frequency is the result of 
a random sampling error. The following positions had the 
listed favorite nucleotide based on the bases with a relative 
frequency higher than the boundary of 90% Cl: positions -1, -7 
and -8 for a T, positions -6 and -11 for an A, position +16 
for a G and position +17 for a C. There is also a very 
unfavorable C region ranging from -5 to -11 positions. This 
means very rarely a DNA with C residues at these positions 
will result in cleavage of this DNA by DNA topoisomerase I.
Furthermore, by considering the occurrence of purine 
versus pyrimidine based on the 90% Cl, a purine rich cluster 
was seen at -2 to -6 region and +1 position. Further 
consideration of the composition of AT and GC base pairs at 
the same level of Cl found that AT rich regions span from 
positions -7 to -11 and positions -15 to -17, a GC rich region 
between positions 14 and 17 was also found. From the above
83
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Figure 26. Plots of confidence levels for each nucleotide
position around a DNA topoisomerase cleavage site. 
The solid line in the center is the expected 
frequency, 30.15% for A and T and 19.85% for G and 
C. A, filled triangle; T, filled square; G, cross 
with a plus; C, empty square with a cross.
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analysis, a general diagram of the sequence around the DNA 
topoisomerase I cleavage site can be constructed and is 
presented in Figure 27. This sequence includes one purine 
rich region and two AT rich regions upstream of the cleavage 
site, one GC rich region downstream of the cleavage site and 
a preferred T at the cleavage site.
The cleavage sites preferred by mitochondrial DNA 
topoisomerase I on the lower strand of the amplified TERM DNA 
fragment were further analyzed (Figure 18B bands 1 and 2). 
After a detailed examination of these sequences, a departure 
from the conclusion mentioned above was seen. All three 
sequences had a G at the -1 position rather than a T and were 
able to form a stem-loop structure by base pairing as shown in 
Figure 28. The two stem-loop structures thus constructed have 
several similar features. First, the loop is GC rich and it 
starts and ends with a G and a T. Second, the cleavage occurs 
inside the loop at the position close to the center of the 
loop. Third, the stem is formed by an AT rich five base- 
paired structure holding together by a total of 11 hydrogen 
bonds. Fourth, two conserved sequences occur at the base of 
the stem and they are a TTNT at the left and a T-TGG at the 
right. None of the other cleavage sites with a G at the -1 
position is able to form such a structure with the above 
mentioned characteristics. Thus, this structure seems to be 
important for the mitochondrial DNA topoisomerase I to 
recognize its substrate for preferential cleavage.
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Figure 27. A diagram of a suggested sequence recognized by DNA 
topoisomerase I.
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Figure 28. A diagram of two proposed cruciform structures 
deduced from mitochondrial DNA topoisomerase I 
preferred sequences.
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4.) Studies of the preferential binding of the enzymes 
to certain types of substrate DNAs.
The similarity between the mitochondrial and bacterial DNA 
topoisomerase I in the linkage to the 5' end of the DNA break 
lead to further investigations in distinguishing between these 
two enzymes. The preferential binding to the single-stranded 
DNA by the bacterial E. coli DNA topoisomerase I has been 
demonstrated (7). In addition, nuclear DNA topoisomerase I 
showed no preference for either single- or double-stranded 
DNA. Therefore, the interaction of the mitochondrial DNA 
topoisomerase I with single- or double-stranded DNA was 
investigated. Two approaches were used to evaluate the 
behavior of the mitochondrial DNA topoisomerase I toward 
single- and double-stranded DNA. The first approach was 
competition assays in the presence of single- or double­
stranded DNA, and the second approach was DNA cleavage assays 
using either single- or double-stranded DNA as substrate.
In the first approach, relaxation of supercoiled DNA was 
measured in the absence and presence of both linear single- 
(heat denatured) and double-stranded DNA. Figure 29 shows a 
densitometric tracing of the results of this experiment. The 
linear DNA used in this experiment is a 795 base pair DNA 
fragment electroeluted from Maelll restriction digested pUC19 
DNA. Panel A shows that relaxation activity of the 
mitochondrial enzyme is inhibited in the presence of both
88
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Figure 29. Densitometric tracing of the result of a
competitive assay with single-stranded or double­
stranded DNA. Panel A, results from mitochondrial 
DNA topoisomerase I treated samples. Panel B, 
results from the bacterial DNA topoisomerase I 
treated samples. Line 1, pUC19 DNA only. Line 2, 
plus enzyme. Line 3, plus enzyme and 42 ng of 
pUC19-795 (a 795 base pair fragment from Mae III 
digested pUC19 DNA.) Line 4, plus enzyme and 42 ng 
of heat denatured pUC19-795.
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single- and double-stranded DNA as indicated by the appearance 
of the supercoiled DNA substrate. However, the relaxation 
activity of the bacterial enzyme is only inhibited by the 
presence of single-stranded DNA (Panel B). A similar result 
was obtained when another fragment of pUC19 DNA (a 333 base 
pairs DNA fragment also electroeluted from the Maelll 
restriction digested pUC19 DNA) was used as substrate (data 
not shown). This result suggests that mitochondrial DNA 
topoisomerase I has no preference for single stranded DNA.
Figure 30 shows the result of the second approach which 
compares the cleavage of single- or double-stranded DNA by the 
nuclear and mitochondrial enzymes. As seen in lanes b and c, 
the cleavage pattern generated by the nuclear enzyme was the 
same when either single- or double-stranded DNA was used. 
Yet, a very weak cleavage by the mitochondrial enzyme was seen 
in lane f when the single-stranded DNA was used. This result 
implicates a preference for a double stranded DNA substrate by 
the mitochondrial enzyme and supplies further evidence that 
mitochondrial DNA topoisomerase I is distinct from the nuclear 
enzyme.
S.) Properties of mitochondrial DNA topoisomerase I 
which differ from those of bacterial DNA 
topoisomerase I
It has been well-documented that the enzymatic activity of
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Figure 30. A result showing the requirement of duplex DNA as 
substrate for the mitochondrial DNA topoisomerase 
I cleavage assay. Lanes a through c, regular DNA 
cleavage assay. Lanes d through f, DNA cleavage 
assay with the heat denatured DNA substrate. Lanes 
a and d, amplified L-ORI DNA with upper strand 
radiolabeled only. Lanes b and e, plus nuclear 
enzyme. Lanes c and f, plus mitochondrial enzyme.
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the bacterial DNA topoisomerase I is dependent upon magnesium 
ions (1). However, eukaryotic DNA topoisomerase I does not 
require magnesium ions for activity, but its activity is 
stimulated many-fold in the presence of optimal amounts of 
magnesium ions (18) . The stimulating effect of magnesium ions 
on mitochondrial DNA topoisomerase I activity was demonstrated 
in section 2, catalytic properties of the enzvme. However, 
the difference in the relaxation reaction conditions for the 
bacterial enzyme and the ones for the nuclear and 
mitochondrial enzymes made the comparison of the magnesium ion 
effect invalid.
To illustrate the real differences in magnesium ion 
requirements, the same buffer system was used to compare the 
effect of magnesium ions on mitochondrial and bacterial 
enzyme. The result in Figure 31 further confirmed the 
difference. Not only does the bacterial enzyme requires 
magnesium ions for its relaxation activity, but also magnesium 
ion concentrations of 20 mM completely inhibit the activity. 
Whereas, mitochondrial enzyme does not require magnesium ion 
for its relaxation activity and is stimulated by magnesium ion 
at concentrations up to 20 mM.
The inability of the bacterial enzyme to relax positively 
supercoiled DNA was also seen with this buffer system (data 
not shown). Furthermore, up to 160 (M of camptothecin was not 
able to inhibit the bacterial enzyme relaxation activity on
92
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Figure 31. The effect of the Mg2+ on the relaxation activity 
of the bacterial and mitochondrial DNA 
topoisomerase I. Lane a, pUC19 DNA only. Lanes b 
through k, bacterial enzyme treated samples. Lanes 
1 through u, mitochondrial enzyme treated samples. 
Lanes b, c, 1, and m, no Mg+2 added, lanes f 
through k, duplicate results with addition of 2.5, 
5, 10, 20 mM of Mg+2. Lanes n through u,the same 
concentrations of Mg+2 as lanes f through k. I, 
supercoiled pUC19 DNA. Ir, relatively relaxed 
pUC19 DNA. IQ and II, completely relaxed and 
nicked pUC19 DNA, respectively.
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negatively supercoiled DNA (data not shown) . These properties 
of the bacterial enzyme clearly differ from those of the 
mitochondrial enzyme (see Figures 9 and 10).
B. Mitochondrial DNA topoisomerase II
1. Purification of the enzyme
The discovery of the knotted P4 phage DNA (73) as a 
substrate for the type II DNA topoisomerase made the detection 
of the enzyme much easier. The P4 DNA is a 10.5 kilobase pair 
knotted circular DNA. Different degrees of the intra- and 
intermolecular knotting causes a smeared DNA pattern in 
agarose gel electrophoresis. Restriction digestion of the P4 
DNA with EcoR I resulted in three fragments of DNA. When 
unknotted by DNA topoisomerase II, the P4 DNA becomes a 
relaxed circular monomer and migrates as a single band (data 
not shown). These experiments were conducted to verify that 
the purified DNA from P4 phage was knotted P4 DNA. The P4 
knotted DNA was used as substrate to isolate mitochondrial DNA 
topoisomerase II and to characterize this type II DNA 
topoisomerase.
Mitochondrial DNA topoisomerase II was partially purified 
from calf thymus mitochondria. The mitochondria were purified 
as described in the previously published procedure (34). The 
purified mitochondria were treated with digitonin to strip off
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the outer mitochondrial membrane, thereby eliminating residual 
cytoplasmic contaminants. The resulting mitoplasts were 
subjected to several cycles of freezing and thawing so as to 
rupture the organelle; the mitochondrial inner membranes and 
associated mitochondrial DNA were collected by 
ultracentrifugation. DNA topoisomerase II was released from 
the collected inner membrane-mtDNA mixture by treatment with 
the non-ionic detergent Triton X-100 in high salt. The 
mitochondrial DNA was removed by polyethylene glycol (PEG) 
precipitation. The resulting supernatant was applied to a 
phosphocellulose column, and the activity of DNA topoisomerase 
II was detected in front of the mitochondrial DNA 
topoisomerase I activity peak with a slight overlap. Active 
fractions were combined and loaded on a hydroxylapatite 
column. The fractions with DNA topoisomerase II activity were 
pooled and dialyzed against storage buffer and kept at -20°C.
As seen in Table III, the mitochondrial DNA topoisomerase 
II has been purified over 3000-fold from the stage of the pure 
mitochondria using this procedure. Since mitochondrial 
proteins make up approximately 25% of total cellular protein, 
this result represents more than a 12,000-fold purification 
relative to whole cell protein. Due to the presence of
nuclease activity mitochondrial DNA topoisomerase II activity 
was impossible to obtain in the early fractions. The total 
activity in fraction V was considered as the total activity 
for the earlier fractions. The overall yield thus calculated
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Table III. Summary of the purification of DNA topoisomerase II
















I CRUDE MITOCHONDRIA 210 1316 11500 8.7 1 100
II PURE MITOCHONDRIA 95 965 11500 11.9 1 100
III MITOPLAST 40 197.5 11500 58.2 4.9 100
IV DILUTED PEG- 
SUPERNATANT
120 87.7 11500 131 11 100
V PHOSPHOCELLULOSE 
COLUMN FRACTION
11.5 0.805 11500 14286 1200 100
1 VI HYDROXYLAPATITE COLUMN FRACTION 0.66 0.085 1320 15529 1305
I VII DIALYZED FRACTION 0.26 0.028 1040 37142 3121 , m  9 ° J
Starting material was 945 grams of fresh calf thymus gland.
Preparation of various intermediate fractions and column chromatography 
was as described in Materials and Methods.
was 9%.
Several marker enzymes were also used to evaluate the 
purity of the mitochondrial preparation throughout the 
isolation procedures. These included glucose-6-phosphate 
dehydrogenase, sulfite oxidase (77), succinic dehydrogenase, 
amine oxidase and DNA polymerases alpha (78) and gamma (71, 
79). All of the enzyme assays showed an increase in the 
purity of the mitochondria from step to step (Table IV). As 
expected, glucose-6-phosphate dehydrogenase activity decreased 
to a very low level in the PEG-supernatant fraction, and the 
succinic dehydrogenase activity was high in this fraction. 
Moreover, the activities of sulfite oxidase and amine oxidase 
decreased significantly. Finally, a DNA polymerase gamma to 
alpha ratio of 78 to 1 in the PEG-supernatant fraction (Table 
V) further indicated the mitochondrial origin of this enzyme 
(33, 34).
The unknotting activity of this purified mitochondrial DNA 
topoisomerase II is demonstrated in Figure 32. This 
unknotting activity requires ATP as cofactor. Without added 
ATP (lane b) no conversion of substrate DNA into the monomer 
was seen. However, in the presence of 1 mM of ATP (lane c), 
almost all of the substrate DNA appeared as an intense, slower 
migrating band. As the mitochondrial enzyme was diluted, the 
intensity of the monomer decreased (lanes d through f).
97

















Table iv . Marker enzyme activities in mitochondrial fractions.
Total Activity 
(Units)
G-6-P DH Succinic DH Amine oxidase Sulfite
Oxidase |
#1 #2 #1 #2 #1 #2 #1 *2 1
Mitochondria 348.6 513 22176 15456 100.7 1504 221.1 112.6
Mitoplast 57.2 34.9 42720 10512 251 1969 41.0 38.1
Matrix 0 14.7 47760 18711 - — 0 0
PEG-
supernatant
0 8.8 175680 23571 72.5 221.6 76.3 36.6
G-6-P DH: Glucose-6-phosphate Dehydrogenase 
Succinic DH: Succinic Dehydrogenase

















Table V. DMA polymerase activities in mitochondrial fractions.




Crude mitochondria 67 287 4.3 / 1
Mitoplast 4 72 1 8 / 1
PEG-supernatant 1.3 101 7 8 / 1
VOVO
Figure 32. P4 unknotting assay of mitochondrial DNA
topoisomerase II in the presence or absence of ATP. 
Lane 1, P4 DNA only; lane 2, plus enzyme minus ATP; 
lane 3-6 contain serial diluted enzyme plus 1 mM 
ATP; lane 3, 1 fil; lane 4, 1/2 /zl; lane 5, 1/4 n 1; 
lane 6, 1/8 /xl. DNA bands labelled M and L are 
monomer and linear P4 DNA, respectively.
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2. Anti tumor drug effect on enzvxne activity There have 
been no previous reports of any purification of the mammalian 
mitochondrial DNA topoisomerase II and the effect of enzyme 
activities by antitumor drugs has not been studied. 
Therefore, the response of the calf thymus mitochondrial DNA 
topoisomerase II to m-AMSA (a DNA intercalating drug) and 
VM-26 (a non-intercalating drug) was tested using the 
unknotting assay of phage P4 DNA. Figure 33 shows the result 
of this experiment. The mitochondrial enzyme was slightly 
inhibited by m-AMSA at a concentration of 0.5 fi M, 
significantly inhibited at 5.0 juM, and completely inhibited at 
50 /nM. A similar profile was obtained with VM-26 although the 
latter drug was not quite as potent an inhibitor as the 
former.
P4 unknotting assays of purified calf thymus nuclear DNA 
topoisomerase II in the presence of m-AMSA and VM-26 resulted 
in similar inhibition patterns. Figure 34 shows the 
comparison of the effects of antitumor drugs on both 
mitochondrial and nuclear enzyme activity after the amount of 
the unknotted DNA generated was quantitated. This result 
suggests that the mitochondrial enzyme is slightly more 
sensitive to both m-AMSA and VM-26 than is the nuclear enzyme.
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Figure 33. P4 unknotting assay of mitochondrial topoisomerase 
II in the presence or absence of antitumor drugs. 
Lane a, P4 DNA only; lane b, P4 DNA plus enzyme 
plus 1 mM ATP; lane c, same as lane b minus ATP. 
Lanes d through g, same as lane b plus the 
indicated amounts of m-AMSA; lane d, 0.5 fM; lane 
e, 5 /zM; lane f, 50 fM; lane q, 150 /zM. Lane 
h, same as lane g minus enzyme. Lanes i through 1, 
same as lane b plus the indicated amounts of VM-26; 
lane i, 0.5 fiM; lane j, 5 /zM; lane k, 50 /zM; lane 
1, 150 juM. Lane m, same as lane 1 minus enzyme.
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Figure 34. Response of nuclear and mitochondrial type II 
topoisomerases to m-AMSA and VM-26. All samples 
contained a starting amount of two units of 
unknotting activity.
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Chapter IV. CONCLUSIONS AND DISCUSSION
Mammalian mitochondria contain both type I and type II 
DNA topoisomerases judging from the results and the 
conclusions of this study. Here, I describe the first 
identification and partial purification of a mammalian 
mitochondrial type II DNA topoisomerase. This type II DNA 
topoisomerase responds similarly to all other type II enzymes 
in its requirement of ATP for its catalytic activity. 
Furthermore, the type II DNA topoisomerase poisons, m-AMSA and 
VM-26, inhibit its unknotting activity more readily than its 
nuclear counterpart, starting at a concentration of 0.5 /iM. 
Due to the scarce amount of this type II enzyme recovered, 
detailed study of this enzyme was not possible. Modification 
of the enzyme isolation and purification procedure in the 
future is needed for further research.
Working with a mitochondrial enzyme is difficult in the 
tremendous amount of tissue required to obtain a substantial 
amount of purified protein unless it exists in quantity in the 
mitochondria. It is further compounded by the possibility of 
nuclear contamination. Even though several marker enzyme 
assays have been employed as an indication of organelle 
origin, the uncertainty remains until proven different.
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However, the investigation of the mammalian mitochondrial 
DNA topoisomerase I in this study supplies several insights as 
to the function of this enzyme. Not only does its property 
differ from the nuclear enzyme in several ways, but it also 
behaves differently from the bacterial enzyme. The modified 
purification procedure (Appendix II) yielded a highly purified 
and stable enzyme which made these investigations possible.
The differences between the mitochondrial and the nuclear 
enzymes can be summarized in three points. First, the nuclear 
DNA topoisomerase I has smaller K,,, and V,,̂  values than those 
of the mitochondrial enzyme. This difference indicates a 
higher affinity for substrate DNA by the nuclear enzyme, 
however, with a lower maximal reaction rate. This result 
could explain the need of more mitochondrial enzyme in 
phosphoryl transfer assay to lend an equivalent amount of 
radiolabeled enzyme as seen from the faint band in the 
mitochondrial enzyme-treated samples (Figure 1).
Second, the mitochondrial enzyme is covalently linked to 
the 5' terminus instead of the 3' terminus of the DNA break. 
This difference in linkage is a strong indication of a unique 
mitochondrial DNA topoisomerase I and disputes the argument 
that the detection of this mitochondrial enzyme could be due 
to nuclear contamination or that mitochondria contain the same 
DNA topoisomerase I as the nuclei do. In this regard, the 
mitochondrial enzyme behaves the same as the bacterial enzyme,
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further suggesting evolution of mitochondria from prokaryotes.
Third, the mitochondrial DNA topoisomerase I prefers 
double stranded DNA as substrate. As seen in Figure 29, the 
mitochondrial enzyme was only able to cleave double-stranded 
DNA substrates while the nuclear enzyme functions on both 
single- and double-stranded DNA. This also correlates with 
the low affinity for supercoiled pUC19 DNA substrate by the 
mitochondrial enzyme since the highly supercoiled DNA has been 
known to have several single-stranded regions, binding to 
which is unfavorable for the mitochondrial enzyme.
In other respects, the mitochondrial and nuclear enzymes 
behave similarly. Both enzymes do not require divalent ions 
for their relaxation activity, though either Mg2+ or Ca2+ can 
stimulate activity. Also, both enzymes are able to relax 
positively and negatively supercoiled DNA. The inhibitory 
effect of ATP and ADP on type I DNA topoisomerases has been 
reported earlier (76), and the studies performed here draw a 
similar conclusion. Moreover, investigation of the inhibitory 
effect of camptothecin, a type I DNA topoisomerase inhibitor, 
indicates similar responses by both the nuclear and the 
mitochondrial enzymes. The inhibitory effect of m-AMSA 
suggests that the conformation of substrate DNA is important 
in regulating the activity of the DNA topoisomerase I. When 
intercalated with m-AMSA, the negatively supercoiled DNA 
becomes relatively positively supercoiled with an increase in
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linking number. Thus, the number of turns needed to convert 
to the relaxed form by the DNA topoisomerase I is decreased. 
After removal of the m-AMSA, the relaxed DNA becomes slightly 
negatively supercoiled and is seen as a loss of enzyme 
activity.
Like the nuclear DNA topoisomerase I, the mitochondrial 
enzyme recognizes specific sites along the DNA substrate as 
seen from the distinct cleavage patterns (Figures 15 through 
17). These patterns are practically the same for both nuclear 
and mitochondrial enzyme, which indicates the recognition of 
the same DNA sequences. However, the attempt to analyze 
recognition sequences by both enzymes yielded no consensus 
sequences. However, a preference for T at the -1 position of 
the cleavage site and a purine rich region 5' adjacent to the 
T is observed by the mitochondrial and the nuclear enzymes. 
This preference is in agreement with results obtained from 
other systems (80).
Of all the cleavage sequences analyzed, three sequences in 
two regions of the lower strand of TERM fragment were 
identified as mitochondrial DNA topoisomerase I preferred 
sites. These sequences have an unusual cleavage of G at the - 
-1 position. These three sequences have sequence elements 
which could lead to the possible formation of cruciform 
structures with distinct features. These features could be a 
key recognition structure by mitochondrial DNA topoisomerase
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I since it prefers double stranded region as substrate. This 
result is in agreement to the report by Edwards et al. (81) 
that a palindromic, single stranded DNA sequence near the SV40 
origin of replication was cleaved by DNA topoisomerase I after 
a G. One point worth mentioning is that the preferred 
cleavage sequences by mitochondrial enzyme located at the TERM 
fragment suggests a role of this enzyme in mitochondrial 
genome transcription.
Though the mitochondrial DNA topoisomerase I is similar to 
the bacterial enzyme in its linkage to the 5' terminus of the 
DNA break, it differs from the bacterial enzyme in all other 
respects. First, no requirement of Mg2+ for the mitochondrial 
enzyme relaxation activity was observed. Second, the 
mitochondrial enzyme can relax both positively and negatively 
supercoiled DNA, whereas the bacterial enzyme only relaxes 
negatively supercoiled DNA. Third, the bacterial enzyme is 
not sensitive to the type I DNA topoisomerase poison 
camptothecin. Fourth, the mitochondrial enzyme prefers
double-stranded DNA as substrate, while the bacterial enzyme 
binds to single-stranded DNA more readily than double-stranded 
DNA.
Thus, the mammalian mitochondrion contains its own type I 
DNA topoisomerase with characteristics different from both 
nuclear and bacterial enzymes. The role of mitochondrial DNA 
topoisomerase I involving transcription of the mitochondrial
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genome is suggested here. Judging from the in vitro results 
that the mitochondrial enzyme has similar catalytic properties 
and the response to camptothecin as the nuclear enzyme, it may 
also be involved in replication and recombination of DNA as 
well as being a target of antitumor drugs in vivo. Further 
studies are required to understand its biological role inside 
the mammalian mitochondria. Such studies might include the 
effects of antitumor drugs on mitochondria, analysis of the 
compositions and amino acid sequence of this mitochondrial 
enzyme, as well as identification of the gene(s) encoding it.
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Appendix I. Isolation of P4 Knotted DNA
a> Titer P4 phage stock using E. coli. strain c2326
1. Grow 50 ml of c2326 in Complete Modified Luria 
Broth (CMLB) overnight or at least 8 hours.
2. Prepare 15 % bottom agar in CMLB using 10 cm 
diameter petri dishes, about 25 ml each.
3. Prepare 7 % soft agar in CMLB kept at 47 °C.
4. Check OD600 and calculate the concentration of 
cells (1 OD = 8 * 1010 cells/ml).
5. Prepare a serial dilutions of P4 phage (PS1) using 
P4 diluent.
6. Mix 0.1 ml of diluted P4 phage with 0.1 ml of c2326 
in a 15 ml conical centrifuge tubes.
7. Let stand for 20 min at 37°C with loosened caps.
8. Add 3 ml of warm soft agar into each tube, tighten 
the cap and invert the tubes several times. 
Immediately pour the suspension on top of the 
bottom agar and swirl the plate to ensure all the 
agar were evenly distributed without bubbles.
9. Repeat step 8 one at a time.
10. Allow the plates to stand at room temperature for 
5 min with the cover half covered.
11. Cover the plates and place the plates upside down 
in a 37°C incubator for 8 to 16 hours.
12. Count the lysed colonies in the countable plates 
and calculate the titer as following:
No. of colonies * dilution factor / 100 = pfu//zl at
that OD.
b> Growth of P4 phage in E. coli. strain C117 
Day 1:
1. Grow C117 in 50 ml of CMLB in a 250 ml Erlenmeyer 
flask without plug at 37°C with vigorous shaking 
overnight but no more than 18 hours.
Day 2:
2. Dilute the overnight culture with 50 ml of fresh 
CMLB and allow to grow for additional 1 hour.
3. Check the OD^ and calculate the cell 
concentration.
4. Add 1 *107 pfu of P4 phage stock to total of
2 * 109 cells (1 fil of P4 phage stock from Dr. Liu 
to 10 ml of 1.2 OD overnight diluted culture).
5. Allow to stand at room temperature for 10 min for 
the cell to adsorb the phage.
6. Add 5 ml of the P4-C117 (1.2 OD) mixture to each
1 L of CMLB in a 2.8 L Flask without plug.
7. Incubate at 37°C with vigorous shaking.
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8. Check the OD̂ ,, every 30 min to monitor the lysis of 
the cells. A sharp drop of OD (a difference of
0.1) indicates the lysis of the cells. (The OD 
could be checked after 3 hours of culture and it 
should be about 0.5.)
9. When lysis begin, add 10 ml of 0.5 M EGTA pH 8.0 to 
each 1 L of culture to prevent the phage 
readsorption.
10. Continue incubation for 1 hour and add 2 ml of 
chloroform to the culture.
11. Incubate for 20 min to complete lysis.
c> Isolation of P4 Phage from the lysed culture
1. Centrifuge the culture at 17,000 xg at 4°C for 20 
min to remove the cell debris. ( 10 K rpm for JA-10 
or 11 K rpm for JA-14). Be careful not to decant 
the chloroform into the centrifuge bottles.
2. Collect the supernatant and kept on ice. Measure 
the total volume.
3. Add PEG 8000 (125 g in 150 ml of H20, dissolved by 
heating in microwave oven) to 10 %, NaCl to 0.5 M 
(37 g) and 2.5 g of MgCl2. Completely dissolve the 
solids with slow stirring.
4. Allow the precipitation to occur overnight at 4°C.
Day 3:
1. Centrifuge at 17,000 xg at 4°C for 30 min.
2. Pour off the supernatant and collect the pellet.
3. Suspend the pellet in 6 ml of P4 diluent and 
centrifuge at 17,000 xg for 30 min.
4. Collect the supernatant and repeat step 3 twice, 
being careful to keep the pellet from the 
supernatant.
5. Combine the supernatants and add CsCl to density cf 
1.42. (Refractive Index = 1.3745 to 1.3755)
6. Ultracentrifuge in 60Ti rotor 60 K rpm for 16 hours 
at 8°C. (VTi 65 at 65 K rpm for at least 5 hours)
Day 4:
1. Two milky colored bands should be seen at the one 
third away from the top and bottom of the tubes.
2. Collect the top (P4 mature phage) and the bottom 
(P4 Head) bands separately using 5 ml syringe with 
20 G needle.
3. Add at least 5 times of the P4 diluent to the P4 
phage and P4 head and centrifuge to pellet the 
phage. (60 K rpm for 2 hours in 60 Ti rotor or 25 
K rpm for 4 hours in SW 27 rotor.)
4. Pour off the supernatant and collect the pellet.
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5. To the P4 phage, add 0.5 ml of P4 diluent and keep 
on ice overnight to completely dissolve the phage. 
Measure the OD260 and adjust to OD = 10. Store the 
phage in dark at 4°C.
6. To the P4 Head, suspend in total of 1 to 4 ml of TS 
pH 8.0 and transfer to a 15 ml COREX tube for the 
P4 DNA.
d> Isolation of P4 Knotted DNA
1. Add equal volume of TS (Tris-NaCl) saturated 
phenol, cover with parafilm and invert several 
times or vortex.
2. Centrifuge at 4000 rpm in JA-20 rotor for 15 min.
3. Transfer the top aqueous layer to another CORVEX 
tube and repeat step 1 and 2.
4. Collect the aqueous layer and add equal volume of 
water saturated ether, mix with a pasteur pipet and 
let stand for 5 min.
5. Remove the top ether layer.
6. Repeat step 4 and 5 three times. (operate under 
the hood)
7. Add 2 volume of 95% ethanol and cover with the 
parafilm. Mix by inverting and keep under -20°C 
overnight.
Day 5:
1. Centrifuge at 0°C for 30 min.
2. Collect the pellets and remove the residual 
ethanol.
3. Resuspend the DNA in TE buffer.
120
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
APPENDIX II. PROTOCOL FOR PURIFICATION OF MITOCHONDRIAL DNA
TOPOISOMERASE I.
A. PREPARATION OF MITOPLASTS FROM CALF LIVER
1. Trim the fat and grind the fresh calf liver.
2. Suspend the ground material in 6 volumes (W/V) of IX MIB
and blend in a blender with a 10 seconds on and off bursts 
twice.
3. Centrifuge at 2000 xg for 30 minutes. (JA-10, 3500 rpm; 
JA-14, 4000 rpm)
4. Collect the supernatant and centrifuge at 8500 xg for 35 
minutes. (JA-10, 7000 rpm; JA-14, 7500 rpm)
5. Collect the pellets and homogenize in 6 volumes (V/V) of
IX MIB. Centrifuge as in step 4.
6. Homogenize in a final volume of 600 ml per Kg of the 
liver with IX MIB. [Crude mitochondria]
7. Apply 80 ml of the crude mitochondrial suspension to a 
two-step sucrose gradient composed of 75 ml of 25% sucrose 
in TE and 90 ml of 42.5% sucrose in TE in a 250 ml 
bottles.
8. Centrifuge at 26,000 g for 75 minutes. (JA-14, 13,000 
rpm)
9. Collect the banded mitochondria at the interface of the 
two sucrose layers with a pipet.
10. Dilute with 2 volumes of TE (10 mM Tris/ 0.1 mM EDTA) and 
centrifuge at 22,000 g for 20 minutes. (JA-14, 12,000 rpm)
11. Collect the pellets and homogenize in 6 volumes (V/V) of 
IX MIB. [Purified mitochondria]
12. Determine the mitochondrial protein concentration by 
BIURET analysis.
13. Add 1 mg of digitonin per 8 mg of mitochondrial protein 
and stir occasionally for 15 min on ice. [Strip outer 
membrane]
14. Dilute with 2 volumes of IX MIB.
15. Centrifuge at 10,000 g for 15 minutes. (JA-14, 8000 rpm)
121
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
16. Collect the pellets and homogenize in 6 volumes (V/V) of 
IX MIB.
17. Repeat step 15.
18. Collect the pellets and homogenize in 50 ml per g of the 
mitochondrial protein with 0.5X MIB (for Freeze/Thaw) or 
50 mM KPi/ 0.1 M KC1/ 15% glycerol (for direct lysis)
(Mitoplast]
B. ISOLATION AND PURIFICATION OF MITOCHONDRIAL DNA
TOPOISOMERASES FROM MITOPLASTS
A. Lysis of the mitoplast and Collection of the supernatant
1. Add Nonidet P40 (NP40) to the mitochondrial suspension 
to a final concentration of 1%.
2. Keep on ice for 30 minutes and then centrifuge at
110,000 g for 13.5 hours. (SW27, 25,000 rpm)
3. Collect the supernatant as SI (0.1 M KC1 supernatant)
4. Homogenize the pellet with 25 ml of PiK-1.0 (50 mM KPi 
/I.0 M KCl/ 15% glycerol) per g of mitochondrial 
protein.
5. Stir for 30 minutes on ice.
6. Centrifuge at 250,000 g for 3 hours. (60 Ti, 57,000 
rpm; SW50.1, 46,000 rpm)
7. Collect the supernatant as S2 (1.0 M KCl supernatant).
8. Homogenize the pellet with 15 ml of PiK-2.0 (50 mM KPi
/ 2.0 M KCl/ 15% glycerol) per g of mitochondrial
protein.
9. Stir for 30 minutes on ice.
10. Centrifuge at 250,000 g for 3 hours. (60 Ti, 57,000 
rpm; SW50.1, 46,000 rpm)
11. Collect the supernatant as S3 (2.0 M KCl supernatant).
B. Column Chromatography
1. PC Column (Phosphocellulose Column)
a. Pack 12.5 ml of PC per g of the mitochondrial protein 
in PiK-0.3 (50 mM KPi/ 0.3 M KCl/ 15% glycerol).
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b. Dilute the S2 with Pik-0 (50 mM KPi/ 15% glycerol) 
[S2:Pik-0 = 3:7] to 0.3 M KCl.
c. Load the diluted sample to the PC column and wash 
with 3 column volumes of the PiK-0.3.
d. Elute the column with a gradient of PiK-0.3 to 
PiK-1.5 in a total of 10 column volumes.
e. Collect in each fraction one tenth of the column 
volume.
f. Topol and/or TopoII assay at 37°C for 15 or 30 
minutes.
g. Combine the active fractions with more than 4 U per 
Ml. [PC-1]
2. HA Column (Hydroxylapatite Column)
a. Pack 4 ml of HA per g of the mitochondrial protein in 
PiK-0.3 (50 mM KPi/ 0.3 M KCl/ 15% glycerol/ pH 7.8).
b. Dilute the PC-1 with Pik-0 (50 mM KPi/ 15% glycerol/ 
pH 8.0) to 0.3 M KCl. [PC-l:Pik-0 = 1:1]
c. Load the diluted sample to the HA column and wash 
with 3 column volumes of the PiK-0.3.
d. Wash with 3 column volumes of Pi-200 (200 mM KPi/ 15% 
glycerol / pH 7.8)
e. Elute the column with a gradient of Pi-200 to Pi-1000 
(1 M KPi/ 15% glycerol/ pH 7.8) in a total of 10 
column volumes.
f. Collect in each fraction one tenth of the column 
volume.
g. Topol and/or TopoII assay at 37°C for 15 or 30 
minutes.
h. Combine the active fractions with more than 4 U per 
Ml. [HA-1]
3. dsDNA-Cellulose Column
a. Pack 1 ml of ds-DNA-C per g of the mitochondrial 
protein in Tris-0.1 (50 mM Tris-HCl/ 0.1 M KCl/ 15% 
glycerol).
b. Dialyze the HA-1 with at least 200 volumes of 
Tris-0.1 for 1 hours twice. (The dialysis bags must 
be dialyzed with cytochrome c before use to prevent 
the adsorbing of the proteins to the membranes.)
c. Load the dialyzed sample to the ds-DNA-C column and 
wash with 3 column volumes of the Tris-0.1.
d. Elute the column with a gradient of Tris-0.1 to 
Tris-0.6 in a total of 10 column volumes.
e. Collect in each fraction one tenth of the column 
volume.
f. Topol and/or TopoII assay at 37°C for 15 or 30 
minutes.
g. Combine the active fractions with more than 4 U per 
Ml. [ds-DNA-1]
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